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Gestational diabetes mellitus (GDM) is a specific form of diabetes affecting about 
7% of all pregnancies 1. GDM usually reverses after delivery, but altered glucose 
homeostasis harms the mother. Moreover, since it translates into fetal hyperglycemia, 
GDM can affect the healthy development of the fetus, with consequences that can be 
experienced in utero and/or at different stages of post-natal life. In particular, the child 
from a GDM pregnancy has higher chance of developing type 2 diabetes (T2D) and 
cardiovascular diseases (CVD) 2–4. Several clinical trials and epidemiological studies in 
patients with either type 1 or 2 diabetes show that exposure to prolonged 
hyperglycemia leaves a long-lasting impression on vascular cells leading to the 
development of vascular complications which persist after glycemic control is achieved. 
The same studies also suggested that a good glycemic control can delay the onset of 
vascular complications in diabetic subjects 5. 
The term “epigenetic” refers to heritable changes in the cellular phenotype that do 
not involve changes in the genotype. There are different kind of epigenetic 
modifications including methylation and acetylation of histones, and DNA methylation, 
and these modifications influence gene expression 6,7. Although the precise 
mechanistic insight is still unclear, epigenetic regulation might be involved in the long-
lasting effect of diabetes on the vascular system 8.  
In this study, we focused our attention on the methyltransferase Enhancer of Zeste 
Homologue 2 (EZH2), that is part of the Polycomb Repressor Complex 2 (PRC2) and 
plays an essential role in the epigenetic maintenance of the trimethylation of lysine 27 
on histone3 (H3K27me3). It has been recently shown that alternative splicing of the 
EZH2 locus yields two major transcriptional variants: EZH2α and EZH2β 9.The two 
isoforms can each not only regulate distinct targets, but also share gene expression 
networks, making the regulation of transcription based on the deposition of the H3K27 
histone mark more complex than previously anticipated 9. 
MicroRNAs (miRNAs) are single-stranded, non-coding RNAs of 19-25 nucleotides 
that normally bind the 3’-untranslated region of target mRNAs and contribute to the 
post-transcriptional regulation of gene expression. A link has been shown between 
EZH2 and some miRNAs 10,11. In particular, miR-101 reportedly affects endothelial 
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function and angiogenesis by targeting and inhibiting EZH2 under normoglycemic 
conditions 12. 
The aim of our study was to investigate the impact of GDM on fetal endothelial 
biology. To this end, we isolated human umbilical vein endothelial cells (HUVECs) from 
the umbilical cords of GDM and control healthy pregnancies. These cells represent a 
good cell model allowing for non-invasive analyses of the effect of the uterine 
environment on the fetal endothelium. The first objective was to investigate the impact 
of GDM on the functional capacity of HUVECs, with particular focus on apoptosis, 
migration, proliferation and tube formation. Next, we evaluated the expression of EZH2 
(both α and β isoforms) and miR-101 to see whether they affect endothelial function in 
diabetic conditions. We first found that cultured GDM-HUVECs demonstrated 
decreased survival and functional capabilities in comparison with HUVECs obtained 
from healthy non-diabetic mothers. Additionally, we have identified a novel underlying 
mechanism involving miR-101 and EZH2 in GDM-elicited endothelial dysfunction. In 
particular, we have found that in HUVECs, EZH2 is both a target of, and a 
transcriptional repressor for, miR-101. Notably we found that among the two recently 
identified EZH2 isoforms, EZH2β is the only one which is both a target of GDM and a 
mediator of some of the GDM-related damaging effects on HUVECs. 
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1.1 Gestational diabetes mellitus (GDM) 
 
1.1.1 Definition and pathophysiology 
For many years, gestational diabetes mellitus (GDM) was defined as any degree of 
glucose intolerance that was first recognized during pregnancy 13, regardless of 
whether the condition may have antedated the pregnancy or persisted after the 
childbirth. This definition facilitated a uniform strategy for detection and classification of 
GDM, but it was limited by imprecision. The ongoing epidemic of obesity and diabetes 
has led to more type 2 diabetes (T2D) in women of childbearing age, resulting in an 
increased number of pregnant women with undiagnosed T2D 14. Therefore, GDM 
classification has been recently revised and consists of a carbohydrate intolerance of 
any degree diagnosed in the second or third trimester of pregnancy, that is not clearly 
overt diabetes 15. Risk factors for gestational diabetes include certain ethnicities, 
obesity, a personal history of GDM, a family history of T2D, maternal age, polycystic 
ovary syndrome, a sedentary lifestyle and exposure to toxic factors 16. According to the 
American Diabetes Association (ADA), GDM complicates approximately 7% of all 
pregnancies, whereas its total incidence is estimated to be up to 17.8% depending 
upon the diagnostic criteria used and the demographic characteristics of the population 
1. The greatest rises in prevalence are predicted to occur in India, China, Latin America 
and the Middle East 17. 
GDM is closely associated with T2D, as they share many key pathophysiological 
characteristics; namely a relative insufficiency of pancreatic β-cell function and insulin 
resistance. During pregnancy, insulin resistance is increased due to the production of 
placental hormones, such as estrogens, cortisol and human placental lactogen (HPL), 
and cytokines including tumor necrosis factor α (TNF-α), which antagonize insulin 
action 18. This increase is additional to the insulin resistance that occurs due to genetic 
susceptibility and/or a suboptimal lifestyle. In the event there is adequate release of 
insulin by the maternal pancreas, normoglycemia is preserved and the embryo is not 
affected. However, when insulin release is insufficient, hyperglycemia occurs and an 
excess amount of glucose is transferred via the placenta to the embryo while maternal 
insulin cannot pass the placental barrier causing fetal hyperglycemia. As a 
consequence the fetal pancreas produces more insulin to counter the increased 
glucose levels leading to hyperinsulinemia and excessive fetal growth (macrosomia) 19. 
Figure 1.1 shows the basic concepts of GDM pathophysiology.  
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Figure 1.1: Pathophysiology of gestational diabetes mellitus 
During pregnancy placental hormones, genetic susceptibility and/or a suboptimal lifestyle lead 
to an increase of maternal insulin resistance and hyperglycemia. Maternal glucose can then 
transfer to the fetus through the fetoplacental circulation, while maternal insulin is unable to 
pass the placental barrier. Maternal hyperglycemia consequently stimulates fetal 
hyperinsulinemia to counter the extra glucose. The high insulin level in the fetus stimulates 
growth which results in fetal macrosomia 
19




GDM usually reverses after delivery, but altered glucose homeostasis harms the 
mother and can lead to health consequences in the fetus. The short-term complications 
for a mother with GDM include pre-eclampsia, polyhydramnios and caesarean section. 
Similarly, the main short-term fetal and neonatal complications include perinatal 
mortality, macrosomia, obstetric trauma, hypoglycemia, hyperbilirubinemia, 
hypocalcemia and cardiac dysfunction 21,22. Additionally, GDM is associated with long-
term complications for both the mother and child, including T2D and cardiovascular 
diseases (CVD) 23. 
 
1.1.2 GDM and long-term maternal outcomes 
It is well established that GDM is associated with an increased risk of developing 
T2D postpartum, occurring as a consequence of insulin resistance developed during 
pregnancy 24. For the majority of women who go on to develop T2D, GDM does resolve 
immediately postpartum, with the loss of placental hormones and the reduction in 
circulating cytokines, but their glucose tolerance worsens with time, such that after 5 
years 13% of such woman have developed T2D 25. In an Australian retrospective study 
of 5470 GDM patients and 783 control subjects (follow up between 1971 and 2003), 
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the risk of developing diabetes increased with time of follow-up and was 9.6 times 
greater for patients with GDM 26.  
GDM is also a risk factor for CVD events. In a large population-based study in 
Ontario, Canada, women who had GDM in pregnancy compared with a matched 
control group were at higher risk of CVD events with an odds ratio of 1.71 (95% CI 1.08 
- 2.69) 27. When adjusted for the risk of development of T2D, this ratio was no longer 
significant because the considerable part of increased CVD risk was attributable to 
progression to T2D. Therefore, a diagnosis of GDM for each woman provides an 
opportunity for intervention to reduce her risk of future T2D and cardiovascular 
complications. 
 
1.1.3 Fetal programming and GDM long-term outcomes for the offspring  
Our knowledge of the role of maternal diabetes in fetal programming started in 1952 
with the “Pedersen hypothesis”. Pedersen proposed that elevated maternal glucose 
crossed the placenta resulting in hyperinsulinemia and excessive fetal growth, thus 
leading to fetal macrosomia 19. In 1980, Freinkel expanded upon the Pedersen 
hypothesis and proposed that excesses of mixed “fuels” including glucose, amino 
acids, lipids, ketones, and possibly altered concentrations of other nutrients, induce 
“teratogenesis”. Importantly, Freinkel suggested that the teratogenic effects resulting 
from exposure to elevated levels of maternal mixed nutrients, and the timing of such 
exposures, might have profound and long-term consequences for the fetus 28. Some 
years later epidemiological studies on birth and death records by David Barker and 
colleagues led to the idea that babies who are born lighter and survived infancy might 
have an increased risk of developing coronary heart disease later in life. This led to the 
“Barker hypothesis” or “fetal programming hypothesis” which states that adverse 
intrauterine environments will have long-term effects on adult health which includes an 
increase in incidence of T2D, hypertension and coronary heart disease 29. The Dutch 
“Hunger Winter” is one of the earliest and best examples of “fetal programming” during 
World War II, when shortages in food supply caused famine in western Netherland’s 
population. The pregnancies during that period were affected by “foetal starvation” 
which ultimately had long-term effects on the health of the newborn 30. What is unique 
about the Dutch Famine as an experimental study on the effects of maternal 
malnutrition, is that the population was strictly circumscribed in time and place and the 
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sudden onset and relief of the famine was imposed on a previously well-nourished 
population 31. 
This concept of fetal programming of adult metabolic diseases is well supported by 
several studies and thus now widely accepted. Discordant human siblings born before 
and after the development of GDM provided compelling evidence that these later life 
phenotypic consequences are caused by the diabetic uterine environment 2. In 
longitudinal studies of the Pima Indians from Arizona, a population that has an 
extremely high prevalence of obesity and T2D, diabetes during pregnancy does 
increase the incidence of T2D in the offspring, principally at a young age 2,4. Moreover 
an association was found between maternal diabetes and age at offspring’s diagnosis 
of T2D in the multiethnic SEARCH for diabetes in youth study 3. This evidence supports 
the concept that exposure to hyperglycemia during fetal development increases the 
subsequent risk of diabetes and cardiovascular complications later in life. The 
molecular mechanisms underlying this developmental programming of metabolic and 
cardiovascular diseases are still largely unclear. However, in addition to genetics, 
epigenetic mechanisms appear to play a key role 32. 
 
1.1.4 Diagnosis and screening 
Even though GDM is a common disorder in pregnancy, it has been difficult to 
compare its frequency among various populations and estimate its global incidence, 
due to the lack of uniform diagnostic criteria 33.Over the last few decades, different 
diagnostic criteria have been applied according to different rationales as presented in 
Table I 34. All these criteria are based on fasting or non-fasting maternal glucose 
concentrations, most usually by means of an oral glucose tolerance test (OGTT) 35–37. 
As the most important issue in GDM is the development of embryonic, neonatal or 
maternal complications, maternal glucose concentrations need to be used to predict 
the development of complications with the highest possible sensitivity and specificity. 
However, the adoption of a low glucose threshold results in overdiagnosis, as many 
women who are not likely to develop complications will be diagnosed as having GDM. 
By contrast, the adoption of a high threshold results in underdiagnosis, as numerous 
women who would go on to develop complications will be diagnosed as not having 
GDM. Even the adoption of an intermediate threshold will result in a lower but serious 
risk for over- and underdiagnosis. Thus, the definition of GDM by means of maternal 
glucose concentrations constitutes a difficult challenge. 
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The Hyperglycemia and Adverse Pregnancy Outcomes (HAPO) study attempted to 
tackle this challenge by assessing 25,505 pregnant women from 15 countries during 
the third trimester of gestation 38. The study pointed out that there is no specific 
threshold for maternal serum glucose over which the chance of developing maternal or 
neonatal complications increases significantly. By contrast, the correlation between the 
degree of glycemia and the probability of adverse outcomes (e.g. neonatal birth weight 
>90th percentile, primary caesarean section, neonatal clinical hypoglycemia, cord-blood 
C-peptide concentrations >90th percentile) is linear 38. 
Based on the data from the HAPO study, in 2010 the International Association of 
Diabetes and Pregnancy Study Groups (IADPSG) decided to set the threshold at an 
odds ratio of 1.75 for developing specific complications, specifically an increase in 
neonatal fat mass, fetal macrosomia and cord C-peptide concentrations >90 percentile, 
compared with mean glucose concentrations. This odds ratio corresponds to a fasting 
plasma glucose of 92 mg/dl, or 180 mg/dl and 153 mg/dl after an OGTT with 75 g of 
glucose at 1 and 2 hours, respectively (Table I) 39. In other words, a diagnosis of GDM 
set by the IADPSG criteria means that the specific woman has a 75% increased odds 
(odds ratio 1.75) of developing complications as compared to a woman with mean 
glucose concentrations. According to the same criteria, if a woman has a fasting 
glucose of more than 126 mg/dl, a random glucose of more than 200 mg/dl or a 
glycosylated hemoglobin (HbA1c) of more than 6.5%, then a diagnosis of pre-existing 
diabetes mellitus (DM) has to be made 40. The IADPSG criteria have a number of 
advantages. They represent a unique opportunity for uniformity in GDM diagnosis, are 
simple and can be compared with similar criteria for DM diagnosis in the non-pregnant 
state. On the other hand, they have been developed based on observational studies of 
GDM complications and cannot necessarily be used as treatment thresholds. In 
addition, they increase the GDM prevalence from 5-6% to 16%, being more inclusive 
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Table I: GDM diagnostic threshold values from various organizations 
*Diagnose GDM if two or more glucose values equal or exceed the threshold values, ^Diagnose 
GDM if one or more glucose values equal or exceed the threshold values. ADA (American 
Diabetes Association), ACOG (American Congress of Obstetricians and Gynecologist, WHO 
(World Health Organization), IADPSG (International Association of the Diabetes and Pregnancy 
Study Group. 
 
Regarding screening for GDM, the latest guidelines drawn up by the Endocrine 
Society (ES) are the first to recommend universal testing for overt DM in early 
pregnancy. A fasting plasma glucose, HbA1c or a random plasma glucose at the first 
prenatal visit (before 13 weeks of pregnancy or as soon as possible thereafter) is 
recommended for those women not known to already have DM. In the event of overt 
DM, a second test is recommended on another day to confirm the diagnosis. In all 
pregnant women in whom no overt DM or GDM has been diagnosed, a 2-hour 75-g 
OGTT should be performed at 24 to 28 weeks of pregnancy 42. 
 
1.1.5 Treatment of GDM 
The beneficial effect of early diagnosis and treatment of GDM or mild carbohydrate 
intolerance during pregnancy has been recently demonstrated by two large randomized 
clinical trials. The Australian Carbohydrate Intolerance Study in Pregnant Women, 
established that GDM treatment in the form of dietary advice, blood glucose monitoring, 
and insulin therapy, as required for glycemic control, reduces serious perinatal 
complications and may also improve health-related quality of life 21. Also, the American 
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Maternal-Fetal Medicine Units Network study provided further compelling evidence that 
among women who have GDM and normal fasting glucose levels, treatment that 
includes dietary intervention and insulin therapy, as necessary, reduces rates of fetal 
overgrowth, cesarean delivery, and preeclampsia 43. Accordingly, the primary 
intervention recommended to women diagnosed with GDM is dietary counseling in 
combination with physical activity and self-monitoring of blood glucose 44,45. If these 
measures are insufficient in terms of achieving optimal glycemic control, subcutaneous 
insulin administration is the therapy of choice as insulin does not cross the placenta 
and is therefore considered harmless to the fetus. However insulin is relatively 
expensive and difficult to administer, it requires education to ensure safe administration 
and moreover it is associated with an increased risk of hypoglycemia and weight gain. 
The use of safe and effective oral anti-hyperglycemic agents may therefore offer 
advantages over insulin but has not yet been formally approved for GDM therapy in all 
countries 46. In this context, two large randomized controlled trials were performed to 
test the effectiveness and safety of metformin 47 and glyburide, a sulphonylurea that 
acts as an insulin secretagogue. 48 From these studies, the authors concluded that both 
metformin and glyburide, alone or with supplemental insulin, were not associated with 
increased perinatal complications as compared to insulin. More studies show that both 
metformin and glyburide have been increasingly and safely used in the treatment of 
GDM 49. However, both medications can cross the placenta and given the growing 
evidence of epigenetic fetal programming in utero, the administration of drugs 
potentially affecting fetal metabolism is of major concern. As long term follow-up data 
on both mother and offspring are lacking, oral anti-hyperglycemic agents should be 
used with caution. 
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1.2 Maternal hyperglycemia and fetal endothelial dysfunction 
 
1.2.1 Biochemical and cellular signaling underlying diabetic vascular 
complications 
Hyperglycemia has been shown to be the major risk factor for the development of 
diabetic complications due to its long-term deleterious effects on various tissues and a 
particular subset of cell types. Indeed most cells are able to reduce the transport of 
glucose inside the cell when they are exposed to hyperglycemia, so that their internal 
glucose concentration remains constant. In contrast, the cells damaged by 
hyperglycemia are those that cannot do this efficiently 50,51. Thus, diabetes selectively 
damages cells, like endothelial cells, mesangial cells, neurons and Schwann cells in 
peripheral nerves, whose glucose transport rate does not decline rapidly as a result of 
hyperglycemia, leading to high glucose concentrations inside the cell.  
High glucose can lead to the activation of several cellular pathways, including 
increased oxidative stress 52–54, enhanced flux into the polyol and hexosamine 
pathways 55, activation of Protein Kinase C (PKC) 56 and increased formation of 
advanced glycation end products (AGEs) 57 as shown in Figure 1.2. Studies in 
mesangial, endothelial, and other cell types have associated hyperglycemic activation 
of these pathways to increased mitochondrial superoxide anion formation (O2-) and 
associated oxidative stress 58, which can ultimately lead to increased formation of extra 
cellular matrix (ECM) proteins in the kidney, contributing to renal dysfunction 59,60.  
In addition, high glucose can activate the pro-inflammatory transcription factor NF-
kB, resulting in increased inflammatory gene expression in part through oxidative 
stress, AGEs, PKC, and MAPKs 61,62. Inflammation can also lead to the acceleration of 
diabetic complications due to detrimental effects on vascular cells and insulin 
resistance in T2D. Furthermore, insulin resistance has been attributed to increased free 
fatty acids which, in conjunction with hyperinsulinemia, lead to dyslipidemia 63. 
Therefore, hyperglycemia and dyslipidemia can alter the expression of inflammatory 
and other pathological genes and proteins related to the development of endothelial 
dysfunction 64, which precedes the pathogenesis of vascular complications in diabetes. 
Similar to other forms of diabetes, GDM is associated with structural and functional 
alterations in various tissues including endothelial dysfunction. It is believed that a 
dysfunctional endothelium could lead to impaired vasodilation, increased leukocyte 
adhesion to the vascular wall and platelet aggregation, and impaired angiogenic 
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properties. Endothelial dysfunction in GDM is likely to be at least partially a 
consequence of hyperglycemia which induces changes in the proliferation and 
inflammatory responses of endothelial cells (ECs) in vitro. Decreased proliferation of 
human umbilical vein endothelial cells (HUVECs) from normal pregnancies exposed to 
elevated glucose have been extensively studied and attributed to increased cell death 
65. Moreover HUVECs isolated from gestational diabetes pregnancies presented 
enhanced monocyte adhesion and altered L-arginine transport and nitric oxide (NO) 
synthesis probably due to an altered uptake and metabolism of adenosine 66,67. 
Fetal endothelial dysfunction is involved in the abnormal vascular development 
caused by GDM, and it might be responsible for the increased cardiovascular risk and 
incidence of T2D observed later in life in the offspring from GDM mothers 68,69. 
The mechanisms that link hyperglycemia to fetal endothelial dysfunction and 
cardiovascular complications in adulthood is still largely unknown and different 
explanations have been proposed including the existence of a “metabolic memory”. 
 
 
Figure 1.2: Biochemical and cellular signaling activated by hyperglycemia  
Insulin resistance and hyperglycemia increase mitochondrial O
2- 
production which activates 
atherogenic signaling pathways. Overproduction of mitochondrial O
2-
, results in DNA strand 
breaks and activation of poly-ADP-ribose polymerase (PARP). PARP ribosylates and inactivates 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The upstream metabolites of the 
interrupted glycolytic pathway are processed through polyol, hexosamine, PKC, or AGEs 
pathways. Activation of transcription factor NF-κB, downstream of the AGE pathway, induces 
transactivation of vascular cell adhesion molecule-1 (VCAM-1) and monocyte chemoattractant 
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protein-1 (MCP-1). Increased flux of FFAs, released from insulin-resistant adipocytes, also 
activates hexosamine, PKC, and AGE pathways. In addition, FFA-induced excess mitochondrial 
O
2-
 production inactivates anti-atherogenic enzymes such as prostacyclin (PGI2) synthase and 




1.2.2 “Metabolic memory” and GDM vascular complications 
The results of more than one clinical trial on T1D and T2D patients have 
demonstrated that the development of diabetic complications persisted even after the 
achievement of glycemic control, suggesting the existence of a “metabolic memory” 
dependent from prior exposure to hyperglycemia. T1D patients in the Diabetes Control 
and Complications Trial (DCCT) under intensive insulin therapy were found to have 
delayed progression of nephropathy, retinopathy, and neuropathy compared with 
patients under conventional therapy 71. The large benefits of the intensive therapy led 
to the premature termination of the DCCT so that all patients could be placed on 
intensive insulin therapy and followed long-term under the subsequent Epidemiology of 
Diabetic Complications and Interventions Trial (EDIC). In line with the DCCT findings, 
long-term follow-up in the EDIC trial demonstrated that patients who were originally in 
the intensive treatment group during the DCCT and continued on intensive therapy for 
the EDIC trial had significantly slower progression of key diabetic microvascular 
complications in comparison to patients who were in the conventional treatment group 
during DCCT, even though they were placed on intensive therapy 5. More recently, 
patients in the continuous intensive treatment group since the beginning of the trials 
were found to also have better outcomes for macrovascular complications including 
stroke, nonfatal heart attack, or death by cardiovascular disease 5, as well as 
decreased progression of coronary artery calcification and intima-media thickness, both 
of which are associated with atherosclerosis 8.  
Long-lasting benefits of glycemic control have also been seen in T2D patients. In 
this context the United Kingdom Prospective Diabetes Study (UKPDS) found that lower 
fasting plasma glucose at the time of diagnosis correlated with decreased 
cardiovascular risk 72,73. In addition, the Steno-2 Study found a decreased risk of 
cardiovascular events and death following intensive multifactorial therapy including 
tight glycemic control 74. 
Overall, the findings from these major clinical trials demonstrate that the exposure 
to prolonged hyperglycemia leaves a long-lasting impression on vascular cells and 
progressively induces the development of vascular complications, which persist after 
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glycemic control is achieved. However, the same studies also demonstrated that good 
glycemic control can delay the onset of diabetic vascular complications. Both lines of 
evidence are compatible with an underlying implication of epigenetic mechanisms. 
Indeed, epigenetic factors allow cells and organisms to respond to changing internal 
and environmental stimuli and additionally confer the ability of the cell to memorize 
these environmental situations. 
 
1.2.3 Models of metabolic memory 
Experimental models provide an opportunity to study the molecular mechanisms 
responsible for metabolic memory in order to design better therapies for diabetic 
patients. Recent research has demonstrated the presence of metabolic memory in 
several animal and cell culture models. Early studies in dogs found that there was a 
persistence of retinal complications even after reversal of hyperglycemia 75. Similar 
results with diabetic rats showed that islet transplantation after 12 weeks of diabetes 
could not reverse the progression of retinopathy compared with the same surgical 
treatment after 6 weeks of diabetes 76. Moreover several studies in streptozotocin 
(STZ)-induced diabetic rats showed that establishment of glycemic control after a short 
period of hyperglycemia had protective effects on NO levels, lipid peroxides, and other 
parameters in the retina. However, reinstitution of physiological glucose concentrations 
after prolonged hyperglycemia failed to reverse increases in oxidative stress, NF-kB 
activity, as well as inflammation, and this was attributed to metabolic memory 73,77. 
The presence of a metabolic memory has also been demonstrated in vascular cell 
models. Early in vitro studies with endothelial cells cultured in high glucose showed 
continued increased expression of genes encoding fibronectin and collagen ECM 
proteins even after normalization of glucose levels 78. A more recent endothelial cell 
model of metabolic memory showed that even a short-term exposure to high 
concentrations of glucose resulted in sustained increases in the expression of the NF-
kB p65 subunit, inflammatory genes, and oxidative stress that persisted even after a 
return to normal glucose levels 79,80. Finally, other recent reports demonstrated the 
persistence of oxidative stress for up to 1 week after glucose normalization and that 
antioxidants or NADPH oxidase inhibitors partially blocked the high glucose effects 81. 
Together, these results suggest a metabolic memory of vascular dysfunction arising 
from acute hyperglycemic spikes or prior chronic exposure to high glucose conditions. 
In addition, these experimental models confirm that strict control of glucose levels is 
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essential to slow down the progression of diabetic complications. Importantly, they also 
suggest that oxidative stress, along with epigenetic mechanisms, may be responsible 
for the sustained metabolic memory over time through multiple cell divisions. 
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1.3 Role of epigenetic factors in GDM vascular complications 
 
1.3.1 Epigenetics and transcriptional regulation of gene expression 
Epigenetics refers to heritable changes in the phenotype that do not involve 
changes in the genotype and include mainly two mechanisms: DNA methylation and 
histone tails modification 6. In the promoter regions, DNA methylation that typically 
occurs at CpG islands reduces gene expression by blocking the binding of transcription 
factors or promoting chromatin packing. Post-translational modifications that occur on 
the histone tails include mainly acetylation, methylation, and phosphorylation 7. Along 
with DNA methylation, these epigenetic modifications make up an additional level of 
gene regulation or code that can be altered without altering the DNA code itself. In 
addition, the numerous combinations of epigenetic modifications allow for flexibility of 
the chromatin and can affect recruitment and binding of various DNA and histone 
binding complexes that recognize specific combinations of chromatin marks, as shown 
in Figure 1.3. Histone binding complexes often contain other chromatin-modifying 
proteins that can further change the chromatin structure. In this context, histone 
acetyltransferases (HATs) mediate histone lysine acetylation, a chromatin mark 
generally associated with euchromatin formation and activation of gene transcription. 
Histone deacetylases (HDACs), on the other hand, mediate the removal of lysine 
acetylation and are found to be components of repressor complexes 82. Overall, histone 
acetylation can occur quite rapidly and is quite dynamic.  
By contrast, histone methylation is considered to be more stable and long lasting. 
Histone methylation occurs on both lysine and arginine residues and is associated with 
either gene activation or repression depending on which residue is modified 7. The SET 
domain-containing family of histone methyltransferases (HMTs), which is named for a 
conserved sequence motif found in three Drosophila proteins, Suppressor of Position 
Effect Variegation, Enhancer of Zeste and Trithorax, are involved in regulating lysine 
methylation 83. Lysine methylation can be quite complex since lysine residues can be 
mono-, di-, or trimethylated by specific HMTs which usually methylate only one 
particular lysine residue. Specifically, histone H3 lysine 4 methylation (H3K4me) is 
typically associated with gene activation while H3K9me, is generally associated with 
gene repression. In addition, there are several other lysine residues, including H3K27, 
H3K36, and H3K79, that can be methylated to various degrees by different HMTs, 
leading to altered gene expression 84. 
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The exciting discovery of the first histone demethylase (KDMs), lysine demethylase 
1 (LSD1) which specifically removes H3K4me 85 and H3K9me marks 86, demonstrated 
that histone lysine methylation can also undergo dynamic regulation. Numerous KDMs 
have since been identified with specificities for different histone lysine residues 87. In 
the context of diabetes, a recent report demonstrated that histone demethylase 
JHDM2A is associated with obesity and affects genes related to metabolism in rodent 
models 88.  
According to an early definition, epigenetics is associated with chromatin changes 
which are transmitted from parents to offspring. However, this concept has been 
revisited and it is now suggested that epigenetic changes have a long lasting effect, 
which can be transmitted at cell division, but that are not necessary perpetual. In other 
words, the epigenetic modifications once written, can still be diluted and possibly 
erased over time under particular circumstances, such as with the use of drugs or 
lifestyle changes 5. The concept of a changeable epigenetic status is important 
because it confers therapeutic hope at different stages of prenatal and postnatal life. 
 
 
Figure 1.3: Regulation of chromatin by histone modifications 
The two major epigenetic modifications are DNA methylation and histone modifications which 
regulate the active or inactive chromatin state. Hypermethylation of the promoter is associated 
with transcriptional silencing due to the loss of affinity for transcriptional factors such as the 
nuclear receptor (NR) and accessibility by the transcriptional machinery. The inactive chromatin 
has increased affinity for methylated DNA-binding proteins (MBPs), which further recruit histone 
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deacetylases (HDACs), DNA methyltransferases (DNMTs), histone methyltransferases (HMTs) 
and other corepressors. Methylated promoters are associated with unique repressive histone 
marks, which classically include trimethylation of histone 3 on lysine 9 (H3K9me3), and 
trimethylation of histone 3 on lysine 27 (H3K27me3). By contrast, unmethylated promoters are 
associated with gene transcription. They have increased affinity for histone acetylases (HATs), 
histone demethylases (HDMs), DNA demethylases (DMEs), and histone marks associated with 
active chromatin, including acetylation of histone H3 on lysine 9 (H3K9Ac) and trimethylation of 




1.3.2 Transmission of epigenetic modifications 
Epigenetic marks are transmitted through multiple cell cycles. While much is known 
about the epigenetic inheritance of DNA methylation, the exact mechanisms 
responsible for the stable transmission of histone modifications are less well 
understood. Replication-associated transmission, histone variants, and chromatin 
remodeling complexes are some of the factors that have been implicated. 
Methylation of histone lysine residues has been shown to be transmitted through 
replication where the methyl-CpG binding protein recruits the HMT SETDB1 to 
chromatin during replication to methylate newly-deposited histones and thus coupling 
the transmission of H3K9 methylation with DNA methylation 89. Evidence has also 
shown that the long-term silencing Polycomb complex remains bound to chromatin 
during replication, possibly binding more than one nucleosome and allowing 
nucleosomes to maintain contact with chromatin even as the replication fork passes 
through. Alternatively, the complex could interact directly with the replication machinery 
90. Another study demonstrated that the Polycomb repressor complex 2 containing the 
HMT EZH2 can bind H3K27me3 modifications at sites of ongoing replication, which 
would then allow transmission or copying of the parental H3K27me3 marks to the new 
histones deposited on the daughter strand 91. Interestingly the Polycomb complex 
family has been recently found to play a role in the epigenetic regulation of pancreatic 
cell regeneration associated with diabetes 92. 
Together, these results highlight the need for further investigation into the 
mechanisms by which diabetes-induced epigenetic changes might be stably 
transmitted through cell replications to establish a transcriptional or metabolic memory 
associated with diabetic complications. 
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1.3.3 Role for microRNAs in epigenetic regulation 
One of the emerging areas of research involves the post-transcriptional regulation 
of gene expression through a recently discovered group of small RNAs, the microRNAs 
(miRNAs). MiRNAs are single-stranded, non-coding RNAs of 19-25 nucleotides that 
normally bind the 3’-untranslated region of target mRNAs, leading to either translational 
repression or RNA degradation 93.  
MiRNAs produced via the canonical pathway are transcribed in the nucleus by RNA 
polymerase II into primary miRNAs (pri-miRNAs) that are several hundred nucleotides 
in length. Subsequently, the microprocessor complex, which consists of Di George 
syndrome Critical Region gene (DGCR8) and the nuclease Drosha, cleaves the pri-
miRNAs, with a stem-loop structure, into miRNA precursors (pre-miRNAs) of 
approximately 60 to 70 nucleotides. In the non-canonical miRNA pathway, miRNAs are 
transcribed directly as endogenous short hairpin RNAs (endo-shRNAs) or derived 
directly by splicing from introns (mirtrons) 94. Next, exportin-5 transports the pre-
miRNAs from the nucleus to the cytoplasm via a RAN-GTP-dependent process. The 
pre-miRNAs are further processed in the cytoplasm by RNase Dicer in association with 
Transactivation Response RNA Binding Protein (TRBP) to final miRNA duplexes of 19-
25 nucleotides. Finally, the mature single-stranded miRNAs are generated and 
incorporated into the RNA-Induced Silencing Complex (RISC) and are ready to interact 
with specific mRNA targets 93. The miRNAs biogenesis pathways are depicted in 
Figure 1.4. 
MiRNAs provide a rapid but reversible system of gene regulation, which also allows 
the cell/tissue/organism to respond to environmental stimuli without changing the DNA 
sequence itself. MiRNAs have been identified as negative regulators in various 
pathways, targeting signaling molecules, transcription factors, and numerous other 
enzymes and proteins. There is also the potential for miRNAs to target chromatin-
modifying enzymes which in turn could also affect transcription and expression of 
miRNAs 95. Therefore, miRNAs may themselves be epigenetically regulated.  
Recent findings have demonstrated a critical role for miRNAs in various diseases. 
They have been found to play key roles in proliferation, differentiation, development, 
and in cancer, where they can act as oncogenes or tumor suppressors 93,96. MiRNAs 
are also associated with the regulation of genes relevant to insulin secretion, 
cholesterol biosynthesis, fat metabolism, adipogenesis and angiogenesis, crucial 
pathways in the pathogenesis of diabetes and its vascular complications 97,98. The role 
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of miRNAs and their potential relationships to epigenetic mechanisms in diabetic 
complications are currently an area of great interest both as a means for understanding 
the molecular pathways leading to these complications and for discovering new 
potential therapeutic targets. 
 
 
Figure 1.4: MiRNA biogenesis pathways 
MiRNAs, produced via the canonical pathway are transcribed from genomic DNA in the nucleus 
as long primary miRNAs (pri-miRNA) by RNA polymerase II. The pri-miRNA transcript forms a 
stem-loop structure that is recognized and processed by Drosha in association with DGCR8 into 
a precursor miRNA (pre-miRNA). In the non-canonical miRNA pathway, miRNA are transcribed 
directly as endogenous short hairpin RNAs (endo-shRNAs) or derived directly by splicing from 
introns (mirtrons) 
94
. The pre-miRNA is then exported to the cytoplasm by exportin 5 and RAN-
GTP-dependent process. In the cytoplasm, pre-miRNA is further processed by RNase activity of 
Dicer and Transactivation Response RNA-Binding Protein (TRBP) complex to form the mature 
double-stranded ~22 nucleotide miRNA. The mature miRNA is then incorporated into the RISC 
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complex which mediates small interfering RNA silencing by degrading the target mRNA or 




1.3.4 MiRNAs as novel regulators of endothelial function  
MiRNAs play a central role in endothelial function regulation. Elimination of most 
endothelial miRNAs by Dicer knockdown in ECs inhibits proliferation and tube 
formation in vitro 99. Moreover, Dicer knockout mice have impaired blood vessel 
development 100. These findings suggest that miRNAs are essential for the 
maintenance of vascular homeostasis.  
The first large analysis of miRNA expression in ECs was carried out in HUVECs 
and identified 15 highly expressed miRNAs and some of their angiogenic mRNA 
targets (Flt-1, Nrp-2, Fgf-R, c-Met, and c-kit), according to prediction algorithms 101. 
Additional studies also profiled the expression of miRNAs in ECs 102. The highly 
expressed miRNAs that were common in at least two of the three studies included miR-
15b, 16, 20, 21, 23a and 23b, 24, 29a and 29b, 31, 99a, 100, 103, 106, 125a and 125b, 
126, 130a, 181a, 191, 221, 222, 320, let-7, let-7b and let-7c 99,101.Several miRNAs have 
also emerged as potential regulators of EC function under diabetic conditions. Wang et 
al. identified that high glucose levels induced miR-320 expression in myocardial 
microvascular ECs. Inhibition of miR-320 improved proliferation and migration, which 
has implications for diabetic-impaired angiogenesis 103. More recently, expression of 
miR-503 was found to be increased in ECs exposed to high glucose levels in vitro. 
Consistently, miR-503 expression also increased in ECs enriched from ischemic limb 
muscles of STZ-induced diabetic mice 104. Moreover, miR-503 expression was 
remarkably higher in the limb muscles and plasma from diabetic patients and inversely 
correlated with expression of cell division cycle 25A, a known target gene that controls 
cell cycle function. Local inhibition of miR-503 promoted vascular wound healing and 
blood-flow recovery in a diabetic mouse model of limb ischemia 104. Expression of 
another miRNA, miR-29c, was increased in microvascular ECs exposed to 
hyperglycemic conditions and in the kidney from diabetic mice. Upregulation of miR-
29c decreased Spry1 protein levels and promoted activation of Rho kinase, which 
suggests that miR-29c may play a role in kidney remodeling during diabetic 
nephropathy 105. Additionally, miR-221 expression increased in ECs in response to 
advanced glycation end products or glucose, and its overexpression reduced c-kit 
expression 106.  
 Dr. Mariantonella Vardeu, “Impact of the diabetic environment on the fetal vasculature: role of microRNA-101 and 
Enhancer of Zeste Homologue 2”, PhD thesis in Biochemistry, Physiology and Molecular Biology of International PhD 
School in Biomolecular and Biotechnological Sciences, University of Sassari. 
30 
MiR-101 is known to affect endothelial function and angiogenesis under normal 
glucose conditions 12 and to target the histone methyltransferase Enhancer of Zester 
Homologue 2 (EZH2) for inhibition 12,107–109. However, its role in the context of diabetes 
is still unexplored. 
 
1.3.5 Enhancer of Zeste Homologue 2 and its role in angiogenesis 
EZH2 is a well characterized epigenetic regulator and is a member of the 
Polycomb-Group (PcG) proteins. PcG proteins function as transcriptional repressors 
that silence specific sets of genes through chromatin modification 110. PcG proteins act 
together in Polycomb Repressive Complexes (PRC). In this context, PRC2 is a multi-
subunit complex which includes EZH2, Suppressor of Zeste 12 (SUZ12), and 
Embryonic Ectoderm Development (EED). A number of other proteins, such as 
retinoblastoma binding proteins 4 and 7 (RBBP4/7), enhance the enzymatic function of 
the complex 111.  
EZH2 is the catalytically active component of PRC2, which holds the evolutionarily 
conserved SET domain that confers its HMT activity. Specifically EZH2 trimethylates 
the histone H3 at lysine 27 (H3K27me3) 112. The H3K27me3 mark subsequently 
recruits PRC1, leading to the propagation of the repressed state through a variety of 
mechanisms, including chromatin compaction and recruitment of other chromatin-
remodeling enzymes, such as DNA methyltransferases 113. PRC1 and PRC2 are 
shown in Figure 1.5. 
Expression profiling indicated that EZH2 promotes angiogenesis in ovarian 
carcinoma 114 and glioblastoma cells 12,109. Moreover, altered EZH2 expression was 
described to affect angiogenesis in bladder cancer cells 115, in HUVECs 116 and in vivo, 
in a mouse model of limb ischemia 117. It was also described that EZH2 expression is 
regulated by miRNAs including miR-26 10, miR-214 11, and miR-101 12,107–109. On the 
other hand, regulatory feedback loops between EZH2 and microRNAs have been 
recently identified in human tumorigenesis 95,118. In this context EZH2 has been recently 
proposed to regulate miR-101 in non-ECs 115,119. The complexity of EZH2-mediated 
gene silencing has further increased since the recent discovery of a novel isoform of 
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Figure 1.5: The Polycomb repressor complexes  
PRC2 is a multi-subunit complex which includes EZH2, which is the catalytically active 
component, Suppressor of Zeste 12 (SUZ12), and Embryonic Ectoderm Development (EED). A 
number of other proteins, such as retinoblastoma binding proteins 4 and 7 (RBBP4/7), enhance 
the enzymatic function of the complex. PRC2 is recruited to chromatin and allows trimethylation 
of histone H3 on lysine 27 (H3K27me3) by EZH2. PRC1 is then recruited to chromatin through 
the recognition of H3K27me3 mark by chromobox (CBX) proteins. RNF2/RING1 homologs are 
E3 ubiquitin ligases for H2A, which is monoubiquitylated at lysine 119. The RYBP repressor 
protein recognizes H2A monoubiquitylation, contributing to transcriptional repression. The grey 
circular shapes in the figure depict other PRC subunits and associated proteins. The figure is 
adapted from http://www.activemotif.com/stem-cell-identity. 
 
1.3.6 Enhancer of Zeste Homologue 2 and its novel isoform: EZH2-β 
It has been recently shown that alternative splicing of the EZH2 locus yields two 
major transcriptional variants: EZH2α and EZH2β 9. 
EZH2α, encoded by 20 exons, is the HMT classically associated with the function of 
the PRC2 complex. EZH2β, a novel isoform, skips exon 4 of EZH2α and utilizes an 
alternative 5′ splice donor on EZH2α exon 8/EZH2β exon 7, as presented in Figure 1.6 
A. Compared with the EZH2α sequence, the shorter EZH2β shows conservation of 
several domains, namely the nuclear localization signals, SANT (DNA-binding 
domains) and the SET domain. Together, the conservation of these domains should 
confer this protein with the ability to localize to the nucleus and function as an HMT. 
Accordingly, this isoform localizes to the cell nucleus, complexes with EED and SUZ12, 
and binds to promoters where it increases H3K27me3 levels, all properties in common 
with EZH2α protein. At the protein sequence level, EZH2α and EZH2β differ by 44 
amino acids, measuring 751 and 707 amino acids, respectively, as shown in Figure 1.6 
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B 9. A highly similar third splice variant encoding five fewer amino acids than EZH2α 
has also been referred to as EZH2. Structural comparison of these closely related 
variants does not reveal any differences that would suggest differing function and 
thereby have been considered interchangeable in the literature.  
 
 
Figure 1.6: Comparative analysis of EZH2 transcriptional variants 
Alternative splicing of the EZH2 locus yields two major transcriptional variants: EZH2α and 
EZH2β. The sites of alternative splicing events are highlighted in red on the reference isoform 
(A). At the protein structure level EZH2α and EZH2β show the conservation of functional 
domains and binding sites of enzymatic co-factors, represented by different colors. Labels 1 and 
2 indicate the locations of deletions in EZH2β compared with EZH2α. A comparison of the 
amino acid sequences highlighting the amino acid differences between the two isoforms is also 




Expression profile experiments performed in pancreatic epithelial cell systems 
combined with adenoviral-mediated introduction of both EZH2 isoforms, using array 
analysis, showed that the two different isoforms can each not only regulate distinct 
targets but also share gene expression networks, making the regulation of transcription 
based on the deposition of the H3K27 histone mark more complex than previously 
anticipated 9. 
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Figure 1.7: Expression patterns of EZH2α and EZH2β 
Arrays analysis shows that of the 28,869 well-annotated genes assessed, 366 unique targets 
(36% of total repressed) are uniquely repressed by EZH2β. EZH2α-generated expression 
profiles display a downregulation of 480 targets (48% of total repressed). Notably, 162 targets 
(16% of total repressed) are repressed by both EZH2α and EZH2β. Both isoforms also induce 
upregulation in the expression of a significant number of targets, which may reflect indirect 
effects mediated by the repression of upstream regulators. Of the genes assayed, 444 (40% of 
total activated) are activated by EZH2β, 382 (34%) by EZH2α and 296 (26%) by both isoforms. 
The overall array data indicate that the novel EZH2β isoform is responsible for the expression 
pattern of its own unique set of genes, in addition to a group of common targets with EZH2α. 




 Dr. Mariantonella Vardeu, “Impact of the diabetic environment on the fetal vasculature: role of microRNA-101 and 
Enhancer of Zeste Homologue 2”, PhD thesis in Biochemistry, Physiology and Molecular Biology of International PhD 
School in Biomolecular and Biotechnological Sciences, University of Sassari. 
34 
1.4 Diagnostic and therapeutic potential of miRNAs in GDM 
vascular complications 
 
1.4.1 MiRNAs with diagnostic potential for vascular complications 
In addition to regulating gene expression inside the cells where they are produced, 
several miRNAs are found in blood and other body fluids in association with proteins, 
exosomes and/or lipoprotein complexes as illustrated in Figure 1.8 120,121. The function 
of circulating miRNAs remains still to be elucidated. In vitro studies indicate that 
miRNAs transported by exosomes or HDL can be transferred in an active form to 
recipient cells thus representing a novel cell-to-cell communication mode 122. 
Circulating miRNAs are very stable and resistant to treatment with ribonucleases, 
freezing/thawing cycles and other drastic experimental conditions 123,124. Consequently, 
serum or plasma samples can be stored at −20 °C or −80 °C for up to several months 
without notable degradation of miRNAs, which suggests that these small RNA 
molecules are sufficiently robust to serve as biomarkers 125. Circulating miRNAs have 
several other advantages as potential biomarkers, indeed they are found not only in 
blood but also in other easily accessible biologic fluids such as urine, saliva, amniotic 
fluid and breast milk 126. Moreover, they can be detected by quantitative real-time PCR 
(qPCR), and most of them are evolutionarily conserved, which facilitates the translation 
of results obtained from in vivo animal studies to human healthcare. Although the 
identification of miRNAs as non-invasive biomarkers in pregnancy is still in the early 
stage, much progress has been made in the initial discovery phase. Some candidate 
miRNAs have been identified in the plasma of T2D patients, such as miR-126 127 and 
miR-503 104, and they seem to be promising biomarkers for monitoring diabetic 
vascular complications. GDM is associated with long-term macrovascular 
complications for both mother and child that can have a devastating effect on quality of 
life and life expectancy. The discovery of biomarkers that could be used to predict 
individuals at risk of serious complications such as cardiovascular disorders would 
enable clinicians to adapt therapeutic approaches and minimize the expected effects of 
the disease. However, reliable biomarkers for these long-term complications of GDM 
are still lacking. 
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Figure 1.8: Blood and other body fluids contain active miRNAs 
MiRNAs can be released by cells and are found in a stable form in body fluids. The miRNAs 
present in the blood are associated with protein complexes such as Argonaute-2, with HDL 
particles, or are transported inside membrane-bound vesicles such as exosomes (1). Circulating 
miRNAs can be taken up in active form through different mechanisms, including receptor-
mediated capture, endocytosis or fusion of exosomes with the plasma membrane of receiving 
cells (2). Transfer of miRNAs between distantly located cells constitutes a potentially new 




1.4.2 MiRNAs as therapeutic targets for angiogenesis 
With the increasing characterization of miRNAs in numerous diseases, the field of 
miRNA therapeutics is emerging. MiRNA-based therapeutics involves modulation of 
disease-associated miRNAs by miRNA antagonists or mimics 129,130. Recent studies 
have shown powerful therapeutic effects of miRNAs in several disease models. For 
example, a miR-122 inhibitor showed efficacy in vivo in suppressing Hepatitis C virus 
infection in primates 131.  
MiRNA antagonists are typically chemically modified single-stranded 
oligonucleotides with complementary sequences to the miRNAs of interest, which 
competitively bind to the endogenous miRNAs. The commonly used chemical 
modifications include cholesterol-conjugated 2’-O-methyl modification (antagomiRs) 
and locked-nucleic acid modification (LNA) 131,132. MiRNA “sponges” contain 
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complementary binding sites for the miRNAs of interest and have the advantage of 
blocking a whole family of related miRNAs or achieving cell-type specific miRNA 
silencing 133. MiRNA mimics can be chemically modified double-stranded miRNAs or 
miRNAs expressed by viral vectors, including retrovirus, lentivirus and adeno-
associated virus.  
MiRNA-based therapeutics is still in the early stages, however, inhibition of some 
miRNAs has been promising for the future treatment of cardiovascular diseases, such 
as miR-92a 134 and the miR-15 family 135. To date, there is only one antagomiR in 
clinical trials; Miravirsen, an inhibitor of miR-122, against the Hepatitis C virus (HCV). 
Just recently, data from the phase 2a trial were released indicating that Miravirsen 
provided continuous and prolonged antiviral activity and was well tolerated in patients 
infected with HCV.  
These promising clinical outcomes promote the research for additional miRNA 
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Chapter II - Aim of the Study 
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Aim of the study  
 
Gestational diabetes mellitus (GDM) is a pregnancy-specific condition concerning 
approximately 7% of all pregnancies and is associated with long term adverse 
outcomes for the offspring. GDM leads to fetal hyperglycemia and endothelial 
dysfunction in the fetal circulation which might be responsible for the increased 
incidence of type 2 diabetes (T2D) and cardiovascular risk observed later in life in the 
offspring 2–4. 
Molecular mechanisms involved in GDM-elicited outcomes are still unclear, 
however epigenetic regulation and microRNAs (miRNAs) are likely to play a role. 
Epigenetic mechanisms induce long-term gene expression changes in response to in 
utero environmental perturbations 32. Moreover, miRNAs control the function of 
endothelial cells (ECs) under physiological and pathological conditions and can target 
the epigenetic machinery 99,101.  
The aim of this study was to investigate the functional and expressional impact of 
GDM on human umbilical vein endothelial cells (HUVECs) focusing on the role of miR-
101 and its target the Enhancer of Zeste Homologue-2 (EZH2). To this end, we 
isolated HUVECs from the umbilical cords of GDM and control healthy pregnancies. 
These cells represent an expedient in vitro model allowing for non-invasive analyses of 
the effect of the uterine environment on the fetal endothelium.  
The first objective was to investigate the impact of GDM on the functional 
capabilities of HUVECs, with particular emphasis on apoptosis, migration, proliferation 
and tube formation. Secondly, we evaluated the expression of EZH2 (both EZH2 α and 
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Chapter III – Materials and Methods 
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3.1 Study subjects and ethics  
 
Umbilical cords were collected upon delivery from 24 full‐term healthy and 22 
full‐term gestational diabetic pregnancies. The characteristics of the donors are 
presented in Table IV.  
The study conforms to the principles outlined in the Declaration of Helsinki. 
Approval was granted by the ethics committee of the Faculty of Medicine, University of 
Sassari, and all mothers were fully informed and provided consent. Patients at 24‐28 
weeks gestation with basal glycemia >95 mg/dL (i.e. following an overnight fast) and 
>155 mg/dL two hours after a 75 gram oral glucose load were diagnosed as having 
gestational diabetes mellitus (GDM).  
Human umbilical vein endothelial cells (HUVECs) were isolated at the University of 
Sassari, Italy, and exported to the University of Bristol, UK, where all experiments were 
performed. Import, storage and use of HUVECs samples in Bristol for this study were 
approved by NRES Committee West Midlands (REC reference: 12/WM/0366; IRAS 
Project Code: 113869). 
 
3.2 Isolation and culture of Human Umbilical Vein Endothelial 
cells (HUVECs) 
 
HUVECs were isolated from the umbilical cord vein of the newborn as described 
previously 136,137.  
The two ends of the cord were cut with a sterile scalpel and a cannula was 
introduced at one end of the vein, which was the widest vessel having a thick lumen as 
shown in Figure 3.1. The vein was washed twice using a 30 ml syringe with 30 ml 
phosphate-buffered saline (PBS) so that the cord was clean and there was no blood or 
clot visible. HUVECs were flushed out after digestion for 10 mins at 37°C with 0.05% 
(w/v) type II collagenase from Clostridium histolyticum (Sigma-Aldrich, UK), prepared in 
medium M199 (Life Technologies, UK) supplemented with 100 U/ml of penicillin G 
sodium salt and 100 μg/ml streptomycin (Life Technologies, UK). The cellular 
suspensions were then collected and centrifuged at 1000×g for 10 minutes. The 
supernatant was carefully discarded and the pellet was resuspended in 5 ml of M199 
medium supplemented with 10% (v/v) fetal calf serum (FCS), 10% (v/v) newborn-calf 
serum (NBCS) (Life Technologies, UK), 2mM glutamine and 1% penicillin/streptomycin.  
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The cells were then plated in 25 cm2 tissue culture flasks (Corning, US) pre‐treated 
with 0.1 % gelatin (Sigma-Aldrich, UK) and cultured in 5% CO2 in a 37°C humidity 
incubator. The medium was changed every two days. After one week culture, the 
adherent cells were harvested with 0.05% trypsin-EDTA (Life Technologies, UK) 
treatment and sub-cultured. From passage 2, HUVECs were cultured in endothelial cell 
basal medium EGM-2 (Lonza, UK), following the addition of a SingleQuots™ Kit 
(Lonza, UK) and additional 8% FBS (10% FBS in total).  
 
 
Figure 3.1 Human umbilical vein and arteries 
The picture indicates the location of the umbilical artery and umbilical vein. The HUVECs are 




Isolated HUVECs were characterized by immunocytochemistry. HUVECs were 
seeded in round glass microscope slides on a 24 multiwell plate at a density of 4x104 
cells/well in EGM-2 10% FBS. The cells were then rinsed in PBS and fixed in 4% PFA 
for 20 minutes at room temperature. Cells were permeabilised with 0.1% Triton X-100 
(Sigma Aldrich, UK) in PBS and then blocked in 0.5% goat serum (Vector Laboratories, 
UK) in PBS for one hour at room temperature. Primary antibodies for human CD-
31/PECAM‑1 (R&D Systems, UK, 1:50), CD-144/VE-Cadherin (Santa Cruz 
Biotechnology, UK 1:50), Von Willebrand Factor (Dako, UK, 1:50) were added in 1% 
goat serum and incubated overnight at 4°C. The cells were washed in PBS three times 
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before being incubated for 1 hour in the dark with anti-mouse secondary antibody, 
1:400 (Invitrogen). 
Finally, the nuclei were counterstained with DAPI 1:1000 (Invitrogen, UK) for 4 
minutes in the dark. After a final wash in PBS, the slides were mounted using a 
mounting medium for fluorescence (Southern Biotech, UK), and cell images were 
captured using an Olympus BX40 microscope, an in-line digital camera and the Image-
Pro Plus (Media Cybernetics, UK) software. HUVECs were used from passages 2 to 6 
to ensure their endothelial characteristics. 
 
3.4 Experiments concerning the exposure of cells to high 
glucose 
 
The experimental medium containing a high concentration of glucose was prepared 
directly before the experiments by solubilizing the appropriate amount of powdered D-
glucose or L-glucose (Sigma-Aldrich, UK) in EGM-2, with subsequent filtration and 
supplementation with 10% FBS and 1% penicillin/streptomycin. The final 
concentrations of glucose in the two media were 12.5 mM and 25 mM.  
HUVECs obtained from the umbilical vein of healthy donors were cultured for 48 
hours with the two glucose concentrations (12.5 mM and 25 mM) to mimic 
hyperglycemic conditions. L‐glucose was used as an osmotic control for each 
concentration of D‐glucose. 
 
3.5 MiRNA and siRNA transient HUVECs transfection 
 
To alter miR-101 and Enhancer of Zeste Homologue 2 (EZH2) levels in GDM-
HUVEC, the cells were seeded on a 6-well plate at a density of 2x105 cells per well in 2 
mL complete EGM‐2 medium and grown for 24 hours until 70–80% confluent. The cells 
were then maintained in OptiMEM serum-free medium (Life Technologies, UK) for 2 
hours prior transfection and then transfected with 12.5 nM of pre-miR-101 (Thermo 
Fisher Scientific, Assay ID: MC11414) anti-miR-101, (Thermo Fisher Scientific, Assay 
ID: MH11414, UK), miRNA scrambled controls (Thermo Fisher Scientific, UK), EZH2 
siRNA (Qiagen, Cat no. SI02665166, UK) or siRNA negative control (Qiagen, UK). 
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The siRNA and miRNA molecules were reconstituted to their final concentration by 
addition of RNAase-free water and stored at -20°C. The final concentration of the 
oligomers was 5 µM for pre-and anti-miR-101, 50 µM for miRNA scrambled control and 
20 µM for EZH2 siRNA and siRNA negative control. Oligonucleotides were transfected 
into HUVECs using Lipofectamine 2000 (Life Technologies, UK). 
Briefly, in sterile tubes was prepared the Mix A containing 100 µl of serum-free 
OptiMEM and 2 µl of Lipofectamine 2000, which was incubated for 15 minutes at room 
temperature. Then the Mix B was prepared containing 100 µl of serum-free OptiMEM 
and the oligomers. Mix A and B were then combined by mixing gently and incubated for 
15 minutes at room temperature. Next, 100 µl of DNA-liposomes complexes were 
added to each well mixing gently and the cells were incubated at 37°C and 5% CO2 for 
5 hours. After 5 hours, the transfection medium was replaced by EGM‐2 (10% FBS) 
and after 48 hours the cells were harvested and RNA and protein expression was 
analyzed by q-PCR and Western blot, respectively. The above mentioned protocol has 
been scaled down to accommodate different cell numbers.  
 
3.6 HUVECs adenoviral transduction experiments 
 
The recombinant adenoviruses carrying human EZH2‐alpha, human EZH2‐beta or 
an empty vector (Null) were kindly provided by Professor Urrutia (Laboratory of 
Epigenetics and Chromatin Dynamics, Mayo Clinic, Rochester, MN, 55905, USA) and 
have been extensively described 9. 
For the adenoviral transduction, HUVECs were seeded on a 12‐well plate at a 
density of 1x105 cells per well in 1 mL complete EGM‐2 medium and grown for 24 
hours until 70–80% confluent. Cells were then infected overnight with adenoviruses 
(Ad) at 150 multiplicity of infection (MOI) in EGM‐2 (10% FBS). The cells were 
harvested after 48 hours and EZH2 RNA and protein expression was analyzed by q-
PCR and Western blot, respectively. 
 
3.7 Apoptosis assay 
 
Apoptosis was assessed using the Cell Death Detection ELISA colorimetric kit 
(Roche Life Scientific, UK) which specifically detects histone-associated DNA 
fragments. During apoptosis, endonucleases cleave the double stranded DNA at 
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internucleosomal regions generating mono- and oligonucleosomes. The DNA 
fragments thus formed are enriched in the cytoplasm of apoptotic cells and can be 
measured. 
The experiment was performed as per the manufacturer’s instructions. HUVECs 
were cultured on 6‐well plates at a density of 2x105 cells per well and grown until 90% 
confluent. The cells where then collected and centrifuged at 400 x g for 5 minutes. The 
supernatant was carefully removed, and the cell pellet was resuspended and incubated 
in lysis buffer for 30 minutes at room temperature. The lysate was then centrifuged at 
13000 x g for 10 minutes and 20 µl of the lysate was transferred to the anti-histone 
antibody coated microplate and was incubated for 90 minutes. The anti-DNA-POD 
conjugate solution was then added to each well and incubated under gentle shaking 
(300 rpm) for 90 minutes at room temperature The solution was removed by up-turning 
the plate and the substrate solution was added to the wells and incubated for 15 
minutes. The absorbance was measured at 405 nm with an ELISA plate reader (Opsys 
MR, Dynex Technologies US) and the obtained values were reported as a fold change 
(vs. controls). 
 
3.8 BrdU proliferation assay 
 
The BrdU assay works on the principle that 5-Bromo-2’deoxy-Uridine (BrdU) is 
incorporated into freshly synthesized DNA. Cells are then fixed and the DNA is partially 
digested which allows the binding of peroxidase-labelled anti-BrdU antibodies. Finally 
peroxidase substrate is added, which is cleaved by the peroxidase enzyme generating 
a chromogenic product. Absorbance is proportional to the amount of BrdU incorporated 
into cellular DNA.  
The BrdU assay was performed by using Cell Proliferation ELISA BrdU colorimetric 
kit (Roche Life Sciences, UK) following the manufacturer’s protocol. Briefly, the 
HUVECs were seeded in 96-well plates at a density of 2x103 cells per well and grown 
for 24 hours until 70–80% confluent. Then then the cells were incubated for 1 hour in 
EGM-2 without FBS and cultured for 24 hours with 0.5% or 10% FBS, in the presence 
of BrdU at a final concentration of 10 µM. After the 24 hours incubation the supernatant 
was removed by up-turning the plate. The DNA in the cells was denatured by 
incubation with FixDenat solution for 30 minutes at room temperature. FixDenat was 
then removed and anti-BrdU-POD was added for 90 minutes. The cells were then 
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washed with the washing buffer and incubated with substrate solution for 10 minutes at 
room temperature until the color development was sufficient for photometric detection.  
The plates were read with an ELISA plate reader (Opsys MR, Dynex Technologies 
US) at 340 nm with the reference wavelength set at 370 nm. The ratio between the 
average proliferative capacity of 0.5% FBS and 10% FBS cultures gave an indication of 
FBS‐stimulated proliferation.  
 
3.9 In vitro scratch assay  
 
The in vitro scratch assay is a method to study cell migration. Cells were seeded in 
a 12‐well plate (1x105 cells/well) and grown until confluence in EGM-2 10% FBS. Once 
a confluent monolayer of cells had formed, the cell monolayer was scratched in a 
straight line with a sterile P200 pipette tip to create a gap in the center of the well. After 
scratching, the medium was aspirated and discarded, and the cells were washed with 
medium to remove debris and to smooth the edge of the scratch. After washing, fresh 
medium supplemented with 2 mM hydroxyurea (Sigma-Aldrich, UK) was added to 
arrest cell growth and the plate was incubated at 37°C and 5% CO2.  
Images were taken at 0, 6 and 10 hours at 5X magnification using a bright field 
inverted microscope (Carl Zeiss, UK). Image J (NIH) was used to calculate the wound 
area at the three time points. The final result obtained was the average speed of 
closure of the wound (in mm2/h). 
 
3.10 Tube formation assay on Matrigel 
 
The tube-formation assay is a well-established in vitro angiogenesis assay based 
on the ability of endothelial cells (ECs) to form three-dimensional capillary-like tubular 
structures, when cultured on a gel of growth factor-reduced basement membrane 
extracts. During the assay, endothelial cells differentiate and directionally migrate to 
form the tubular polygonal networks of blood vessels. 
Growth Factor Reduced Matrigel (Corning, UK) was thawed overnight at 4°C and 
kept on ice before being added to 96 well plates; 40 µL of Matrigel were then 
distributed to each well and allowed to solidify at 37°C for 30 minutes. HUVECs were 
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placed on Matrigel in triplicate, at a density of 1.5X104 cells/well in 100 µL of complete 
EGM-2, and incubated for 24 hours at 37°C in a humidified atmosphere with 5% CO2. 
Images were taken after 6 and 24 hours at 5X magnification using a bright field 
inverted microscope. Image J was used to calculate the total tube length (mm) as a 
parameter of angiogenic capacity in vitro. 
 
3.11 Total RNA isolation for mRNA and miRNA analysis 
 
RNA was isolated from cultured cells using the miRNeasy Mini kit (Qiagen, UK) 
which enables purification of total RNA, including small RNAs from approximately 18 
nucleotides, such as miRNAs.  
RNA was eluted with 35 µl of RNAase-free water. The concentration of RNA was 
determined by Nanodrop (Thermo Scientific, UK) and A260/A280 ratios were also 
calculated for each sample to assess the purity of RNA. Samples with ratios smaller 
than 1.7 or greater than 2.1 were discarded.  
 
3.12 Quantitative Reverse Transcription Polymerase Chain 
Reaction (qRT-PCR) for mRNA 
 
The qRT-PCR is a combination of two steps including reverse transcription and 
quantitative polymerase chain reaction. In the first step, an input of 300 ng of total RNA 
was reverse transcribed using QuantiTect Reverse Transcription kit (Qiagen, UK) 
according to the manufacturer’s protocol. RNA was reverse transcribed into cDNA 
using random hexamer primers. The cDNA was then distributed to the appropriate 
wells of a 96 well plates with gene‐specific primers for EZH2 (Sigma), EZH2 total, 
EZH2‐α or EZH2‐β 9 and Power SYBR Green qPCR Master Mix (Life Technologies, 
UK), and quantified using the LightCycler480 qPCR detection system (Roche Life 
Sciences, UK). 
Levels of mRNA were normalized to β‐actin, selected as the reference gene. 
Relative levels of mRNAs were calculated from threshold cycle (Ct) values using the 
2^(‐ΔΔCt) method. Using this method, we obtained the fold changes in gene 
expression normalized to an internal reference gene 138. The primer sequences used 
are presented in Table II.  
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Table II: Details of primer sequences used for this study. 
 
3.13 Quantitative Reverse Transcription Polymerase Chain 
Reaction (qRT-PCR) for microRNA 
 
For miRNA analyses, reverse transcription was performed using the TaqMan 
MicroRNA Reverse Transcription kit (Life Technologies, UK). All reverse transcription 
reactions were performed in accordance with the manufacturers’ protocols using an 
input of 10 ng RNA for each reaction. Real‐time PCR was performed using the TaqMan 
universal master mix with the LightCycler480 qPCR detection system (Roche Life 
Science, UK). Individual microRNA primers for both RT and qPCR were included with 
TaqMan MicroRNA assay sets (Life Technologies, UK). U6 snRNA (Thermo Fisher 
Scientific, Assay ID: 001973) was used as endogenous control for normalization. 
Relative levels of mRNAs and miRNAs were calculated from the threshold cycle (Ct) 
values using the 2^(‐ΔΔCt) method 138. 
 
3.14 Western blot experiments 
 
Cell nuclear extracts were prepared using a previously published protocol 139. 
Briefly, cells were washed twice with cold PBS then resuspended in buffer A (10mM 
Hepes pH 7.5, 10mM KCl, 1.5mM MgCl2, 0.34M Sucrose, 10% Glycerol, 0.1% 
TritonX‐100) supplemented with protease inhibitors (1mM DTT, 0.5mM PMSF, 2 μl/ml 
Protease Inhibitors Cocktails, Sigma-Aldrich,. UK) and incubated at 4°C on a rotator for 
30 minutes to improve lysis. Nuclei were isolated by centrifugation at 6500×g for 5 
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minutes at 4 °C, washed once with buffer A (depleted of Triton X‐100) and 
subsequently resuspended in buffer B (3 mM EDTA, 0.2 mM EGTA, plus protease 
inhibitors).  
Nuclear protein fractions extracted from HUVECs were electrophoresed through 
10% Bis-Tris gel and transferred to PVDF membranes, 0.2 µm pores, (GE Life 
Sciences, UK) by the Bio-Rad wet transfer system. Blots were blocked for 2 hours in 
5% BSA solubilized in TBS-Tween  then probed overnight with antibodies against 
EZH2 (Active Motif, 1:2000); EZH2 total (1:500), EZH2‐alpha (1:500), EZH2-beta 
(1:500) 9, anti‐trimethyl‐Histone H3 (Lys27) (UPSTATE Cell Signaling, US, 1:2000); 
anti‐Histone H3 (Active Motif, UK, 1:2000); anti‐Lamin A/C (Active Motif, UK 1:1000). 
After three washes (TBS + 0.05% Tween 20) blots were stained with HRP-conjugated 
secondary antibodies (Santa Cruz Biotechnology). Bands were visualized using the 
ECL prime system and photographic film (GE Life Sciences, UK) and quantified using 
Image J (NIH). 
 
3.15 Chromatin immunoprecipitation (ChIP) 
 
ChIP assays were performed in order to study EZH2 binding to the miR-101 
promoter in both GDM-HUVECs and healthy HUVECs or in healthy HUVECs exposed 
to high concentrations of D-glucose (25 mM). Cells were fixed in 1% 
formaldehyde/PBS to cross-link proteins to DNA. After 10 minutes of incubation at RT, 
the cross-linking has been stopped by adding glycine to a final concentration of 0.125 
M. The cells were then washed three times in PBS and lysed in SDS buffer (100 mM 
NaCl, 50 mM Tris-HCl (pH 8), 5 mM EDTA (pH 8), 0.2% NaN3, SDS 0.5%). The 
chromatin pellet has been obtained by centrifuging 6 min at 1200 rpm at 4°C. The only 
supernatant was kept and resuspended to the final volume of 300 μl with ice-cold IP 
Buffer (1 vol of SDS Buffer : 0.5 vol Triton Dilution Buffer). Triton dilution buffer was 
made with 100 mM Tris-HCl (pH 8.6), 100 mM NaCl, 5 mM EDTA (pH 8), 0.2% NaN3, 
5% Triton-X100. 
The chromatin was sonicated (3x9 cycles 30”ON/30”OFF) to an average DNA 
length of 400–500bp using a Bioruptor sonicator (Diagenode, Belgium). 
Immunoprecipitation was performed in 1 ml volume with the addition of 3‐5 μg of the 
EZH2 antibody (Active Motif, UK), H3K27me3 antibody (Merck Millipore, UK) and 
control IgGs (Merck Millipore, UK). The following day, immune complexes were 
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collected with purified protein A‐magnetic beads (Life Technologies, UK) for 3 hours at 
4 °C with rotation, washed and DNA eluted by reverse crosslinking at 65 °C for 4 hours. 
Aliquots of immunoprecipitated DNA were analyzed in triplicate by real‐time 
quantitative PCR analysis with Power SYBR Green qPCR Master Mix (Life 
Technologies, UK) and primers specific for the putative regulatory region of miR‐101 
gene (UCSC Genome Browser, Table III) bound by EZH2 and H3K27me3 within the 
miR‐101 transcription start site (Chr1: 65532194). ChIP‐enriched DNA on the target 
genomic regions was assessed relative to the input DNA and IgG control. 
 
 
Table III: PCR primers used for amplification of miR-101 promoter regions. 
 
3.16 Molecular cloning of mir-101 promoter and activity 
assessment by luciferase reporter assay 
 
The putative regulatory element of the mir‐101 promoter was cloned by PCR (KOD 
polymerase, MERCK Millipore, UK) from human genomic DNA. A larger fragment was 
initially cloned using primers (forward 5’‐CTCGGTTTCTCTGCACGTTCG‐3’ and 
reverse 5’‐GGATTATAAAGCTAGGAGGCT‐3’) and a second nested PCR was 
performed to add clamp and restriction endonuclease NheI and BglII (NEBiolabs, UK) 
recognition sites respectively using GCACGCTAGCCTCGGTTTCTCTGCACGTTCG 
and GCACAGATCTGACAGCAGATTCCATTAG. The second fragment including 
nucleotides 65532188 to 65531494 (Homo Sapiens Chromosome1, GRCh37.p13 
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primary assembly) was cloned upstream (NHE1‐BglII sites) of the SV40 promoter of 
the pGL3‐Promoter Luciferase Reporter Vector (Promega Corporation, UK). 
For constructs transfection HUVECs were seeded in 24‐well plates at a density of 
6x104 cells per well in 0.5 mL complete EGM‐2 medium and grown for 24 hours. Cells 
were then co‐transfected with 0.075 μg renilla (pRLTK, internal control (Promega 
Corporation, UK), 0.75 μg pGL3 (control vector) or 0.75 μg of pGL3 mir‐101 promoter 
(all Promega Corporation, UK), along with 200 μl OptiMEM. Luciferase reporter vectors 
were transfected by using Lipofectamine 2000 (Life Technologies, UK) for 5 hours in 
OptiMem. Cells were then transduced with adenovirus overnight. Three days after 
transfection, cells were harvested and assayed with the Dual‐Luciferase Assay system 
(Promega Corporation, UK), according to the manufacturer’s protocol.  
The readings were performed using a Glomax 96 microplate luminometer 
(Promega, UK). Each treatment was performed in triplicate in three independent 
experiments. The results were expressed as relative luciferase activity. 
 
3.17 Statistical analysis 
 
Data are expressed as mean ± standard error of the mean (SEM) from at least 
three independent experiments. Data were assessed for normality using the 
Shapiro‐Wilk test, and differences in two‐group comparisons were tested using the 
unpaired or paired Student’s t‐test, where relevant (for parametric data) or the 
Mann‐Whitney U test (for non‐parametric data). Where there were three or more 
groups, a one‐way ANOVA was performed with a Tukey post‐hoc test. All statistical 
analyses were performed using GraphPad Prism for Windows v6.0 (GraphPad 
Software Inc.). P values < 0.05 were considered statistically significant. 
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Chapter IV - Results 
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4.1 HUVECs isolation and characterization  
 
HUVECs collected from the umbilical cords of newborns delivered by gestational 
diabetes mellitus (GDM) mothers. GDM-HUVECs have been considered an expedient 
in vitro model to study the molecular consequences of long term, chronic 
hyperglycemia 67,140  
Therefore, in order to perform our experiments, we first isolated HUVECs from the 
umbilical cord vein of both healthy and GDM-complicated pregnancies. The 
characteristics of the donors are presented below in Table IV.  
 
 
Table IV: Characteristics of the study subjects  
No statistically significant differences were found between the two groups for any of the 
parameters reported above. Quantitative data are expressed as mean ± standard deviation (SD) 
 
Isolated HUVECs were then characterized by immunocytochemical analysis for 
three reported endothelial cell (EC) markers 141,142: Cluster of Differentiation 31 (CD-
31), Cluster of differentiation 44 (CD-144) and Von Willebrand Factor (vWf). As shown 
in Figure 4.1, HUVECs were positive for CD-31 (A), CD-144 (B) and vWF (C) In 
negative controls, where the primary antibody had been omitted, no fluorescent signal 
was detected (D). These results confirmed the endothelial cell identity of HUVECs 
isolated with our protocol 136,137.  
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Figure 4.1: Immunofluorescence analysis of HUVECs  
HUVECs were isolated from umbilical cords of both GDM and healthy control pregnancies and 
stained with primary antibodies against CD-31 (A), CD-144 (B) or vWF (C). Nuclei are stained 
with DAPI (blue). The images show that HUVECs are positive for the endothelial cell markers. 
Negative control HUVECs incubated only with the secondary antibody (green) demonstrate no 
false positives (D). Images were captured at 40X magnification using an Olympus BX40 
microscope, an in-line digital camera and the Image-Pro Plus software. 
 
4.2 Gestational diabetes mellitus induces phenotypic 
alterations in HUVECs 
 
In order to investigate potential modifications elicited by GDM in the HUVECs’ 
phenotype, we cultured the cells (from both normal and GDM pregnancies) in vitro for 
several passages under physiological glucose conditions.  
As expected GDM-HUVECs showed an increase in the relative apoptotic activity 
compared to healthy HUVECs controls (Figure 4.2 A) and a lower proliferative index 
after stimulation with fetal bovine serum (Figure 4.2 B). Moreover, GDM-HUVECs 
presented a reduced capacity to form cellular networks on Matrigel (Figure 4.2 C) and 
an impaired migration capability measured using a scratch assay (Figure 4.2 D). 
Our results are consistent with the hypothesized mechanism where hyperglycemia 
leads to endothelial dysfunction thus promoting diabetic vascular complications. 
Moreover these GDM-induced phenotypic alterations were observed after 5 to 6 
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passages in GDM-HUVECs cultured under normal glucose conditions, which suggests 
that they likely mimic long-term effects of the GDM in utero environment. 
 
 
Figure 4.2: Phenotypic characterization of GDM-HUVECs  
The graphs show that in comparison with Healthy-HUVECs, GDM-HUVECs presented an 
increased apoptosis rate (assessed using a Cell Death Detection ELISA and expressed as 
normalized absorbance units) (A) and an impaired capacity to proliferate (evaluated by BrdU 
incorporation assay and expressed as the ratio between the BrdU incorporation values in 0.5%  
and 10% FBS conditions) (B). Moreover GDM-HUVECs showed an impaired capacity to form 
capillary-like structures on Matrigel (C) and to migrate and close a gap in a scratch assay (Scale 
bar 0.5 mm) (D). All data are presented as mean ± standard error of the mean (SEM), *P<0.05 
**P<0.01, and ***P<0.001 vs. healthy-HUVECs group. The number of donors used to prepare 
the tested HUVECs is reported on each graph. 
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4.3 MiR-101 is upregulated in HUVECs exposed to diabetic 
uterine environment 
 
Besides classical gene regulation, miRNAs have emerged as post-transcriptional 
regulators of angiogenesis 99,100. It has been recently shown that miR-101 upregulation 
exerted an anti-angiogenic effect on ECs under normal glucose conditions 12. 
In order to explore the expressional levels of miR-101 in ECs exposed to 
hyperglycemia, we performed quantitative polymerase chain reaction (qPCR) analysis 
on GDM-HUVECs and healthy-HUVECs. We used the small nuclear RNA U6 
(snRNAU6) as reference control, which was uniformly expressed in HUVECs in the 
presence or absence of the diabetic condition. 
As showed in Figure 4.3, miR-101 expression was higher (≈ 3 fold increase ± 
0.9169, P<0.01) in GDM-HUVECs when compared to healthy HUVECs, thus 
suggesting a potential involvement of miR-101 in the functional changes previously 
observed in GDM-HUVECs (Figure 4.1). 
 
 
Figure 4.3: MiR 101 mRNA expression in GDM HUVECs 
MiR-101 mRNA expression was assessed by qPCR in both GDM and healthy-HUVECs. The 
relative expression of miR-101 (normalized to snRNAU6) is higher in GDM-HUVECs when 
compared with that in healthy-HUVECs. Data are presented as mean ± SEM, **P<0.01 v.s 
healthy-HUVECs group. The number of donors used to prepare the tested HUVECs is reported 
on the graph. 
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4.4 Effect of miR-101 dysregulation on GDM-HUVEC phenotype 
 
To clarify the role of miR-101 on GDM-HUVEC phenotype, we first altered 
intracellular miR-101 levels by transfecting the cells with pre-miR-101 (to increase the 
miR-101 expression), anti-miR-101 (to decrease miR-101 expression) or a scramble 
sequence as a control (GDM-Scr). Figure 4.4 shows miR-101 expressional changes in 
response to successful transfection. 
 
 
Figure 4.4: MiR-101 modulation in GDM-HUVECs  
GDM-HUVECs were transfected with a precursor (GDM-pre-miR-101), inhibitor (GDM-anti-miR-
101), or a scramble control (GDM-Scr) to modulate miR-101 levels. MiR-101 expression was 
tested by qPCR after 48 hours transfection. The graphs shows that miR-101 levels were 
effectively altered after transfection. Data are presented as mean ± SEM, *P<0.05 vs. GDM-Scr 
group. The number of donors used to prepare the tested HUVECs is reported on the graph. 
 
To understand whether miR-101 is responsible for GDM-HUVECs’ impaired 
capabilities, we performed functional assays on GDM-HUVECs previously transfected 
with pre- miR-101 and anti-miR-101. We also used healthy HUVECs transfected with a 
scramble sequence (Healthy-Scr) as an additional control. 
We found that anti-miR-101 had an anti-apoptotic effect on GDM-HUVECs (≈0.8 
fold decrease ± 0.084 vs. GDM-Scr P<0.05), while a supplementary increase of miR-
101 levels did not raise the apoptotic index (Figure 4.5 A). By contrast the proliferation 
capacity of GDM-HUVEC was unaffected by the forced miR-101 expressional changes 
(Figure 4.5 B). 
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Figure 4.5: Effect of miR-101 modulation on GDM-HUVEC survival and proliferation  
GDM-HUVECs were transfected with pre-miR-101 or anti-miR-101 using scrambled sequences 
as controls (Healthy-Scr. and GDM-Scr). Anti-miR-101 reduced the relative apoptotic activity in 
GDM-HUVECs (A), but it did not affect cell proliferation (B). All data are expressed as mean ± 
SEM. †P<0.05 vs. GDM-Scr. The number of donors used to prepare the tested HUVECs is 
reported in each panel. 
 
Although an anti-angiogenic property of miR-101 on normal HUVECs has already 
been reported (Smits et al. 2011), its effect on GDM-HUVEC has not been 
investigated. 
 We observed that pre-miR-101 reduced the already compromised migratory 
capacity in GDM-HUVECs (0.060 ± 0.003 vs. 0.146 ± 0.016 mm2/h, P<0.05), whereas 
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Figure 4.6: Effect of miR-101 modulation on GDM-HUVEC migration capabilities 
GDM-HUVECs were transfected with pre-miR-101 or anti-miR-101 using scrambled sequences 
as controls (Healthy-Scr and GDM-Scr). The graph shows that pre-miR-101 reduced the 
migratory capacity (expressed in mm
2
/h as the velocity of gap closure of the wounded area), 
whereas anti-miR-101 elicited no effect (scale bar 0.5 mm). All data are expressed as mean ± 
SEM. *P<0.05 and **P<0.01 vs Healthy-Scr. The number of donors used to prepare the tested 
HUVECs is reported in each panel. 
 
Moreover we found that miR-101 inhibition restored the GDM-HUVECs’ angiogenic 
capacity measured as capillary like-tube formation on Matrigel (17.55 ± 0.991 vs. 11.63 
± 2.117 mm, P<0.05), while pre-miR-101 further decreased the capillary-like structures 
of GDM-HUVECs compared to GDM-Scr (4.741 ± 1.363 vs. 11.63 ± 2.117 mm, 
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Figure 4.7: Effect of miR-101 modulation on GDM-HUVEC angiogenic capabilities 
GDM-HUVECs were transfected with pre-miR-101 or anti-miR-101, using scrambled sequences 
as controls (Healthy-Scr. and GDM-Scr.). The angiogenic capacity of GDM-HUVECs (measured 
by network formation on Matrigel) was improved by anti-miR-101. Pre-mir-101 decreased the 
already compromised GDM-HUVECs’ angiogenic capabilities. All data are expressed as mean ± 
SEM. *P<0.05 and vs. Healthy-Scr; †P<0.05 vs. GDM-Scr. The number of donors used to 
prepare the tested HUVECs is reported in each panel. 
 
From this experiments, we suggest that miR-101 upregulation in GDM-HUVECs is 
responsible of the impaired functional and angiogenic capacities presented by these 
cells. 
 
4.5 Enhancer of Zeste Homologue 2 is downregulated in GDM-
HUVECs 
 
Previous studies have shown that Enhancer of Zest Homologue 2 (EZH2) is one of 
the targets of miR-101 and regulates angiogenesis 12,107,108. Moreover, it has been 
recently demonstrated that the EZH2 locus generates, by alternative splicing, two 
major isoforms: EZH2α and EZH2β. Notably, the two different isoforms can each not 
only regulate distinct targets, but also share gene expression networks 9.As miR-101 is 
upregulated in GDM-HUVECs we had a look at EZH2 mRNA expression in these cells 
by qPCR. Consistently, the mRNA levels of EZH2 were reduced in GDM-HUVECs in 
comparison with healthy HUVECs (0.557 ± 0.067 vs. 1.736 ±0.442, P<0.05) (Figure 4.8 
A). Interestingly, we noticed that the EZH2β isoform was decreased in GDM-HUVECs 
(0.860 ± 0.102 vs. 2.025 ± 0.513, P<0.05, Figure 4.8 B), whereas the EZH2α levels 
were unchanged, (1.167 ± 0.112 vs. 1.575 ± 0.245, Figure 4.8 C). 
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Figure 4.8: EZH2 mRNA expression in GDM-HUVECs  
EZH2 mRNA expression was assessed by qPCR in both GDM and Healthy-HUVECs. The 
relative mRNA levels of EZH2 (normalized to β-actin) (A), especially of EZH2β, were 
significantly reduced in GDM-HUVECs in comparison with Healthy-HUVECs (B), whereas the 
relative expression of EZH2α was not (C). All data are presented as mean ± SEM. *P<0.05 vs. 
Healthy-HUVECs. The number of donors used to prepare the tested HUVECs is reported in 
each panel. 
 
EZH2 protein levels were also reduced in GDM-HUVECs in comparison to healthy 
HUVECs as shown by Western blotting analysis (Figure 4.9 A). EZH2 proteins function 
as the key histone code writers of the trimethylation of histone H3 on lysine 27 
(H3K27m3) that leads to long-term epigenetic gene silencing 112. Accordingly we found 
that the levels of H3K27m3 protein were also decreased in GDM HUVECs compared to 
healthy HUVECs. (Figure 4.9 B). 
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Figure 4.9: EZH2 and H3K27m3 proteins levels in GDM-HUVECs  
Protein levels were determined by Western blotting analysis in GDM and Healthy-HUVECs. The 
graphs show that EZH2 was decreased in GDM-HUVECs compared to Healthy-HUVECs 
(normalized to lamin A/C) (A). Accordingly, the H3K27m3, derived by EZH2 enzymatic activity, 
was also decreased (normalized to total H3) (B). Data are presented as mean ± SEM. *P<0.05 
vs. Healthy-HUVECs. The number of donors used to prepare the tested HUVECs is reported in 
each panel. 
 
To clarify the enzymatic activity of EZH2 isoforms on H3K27m3 in GDM-HUVECs, 
we separately overexpressed each isoform by using adenovirus-based (Ad.) 
transductions. An adenovirus carrying an empty vector (Ad.Null) was used as control. 
Figure 4.10 A shows increased mRNA levels of EZH2α (≈ 238 fold increase ± 43.98, 
P<0.001), and EZH2β (≈ 323 fold increase ± 63.72, P<0.001) after gene transfer. We 
observed that in GDM-HUVECs, Ad.EZH2β increased the H3K27m3 levels (≈ 2 fold 
increase ± 0.345, P<0.05 in comparison with Ad.Null), whereas Ad.EZH2α had no 
impact (Figure 4.10 B). From this experiment we concluded that in GDM-HUVECs only 
EZH2β may be involved in H3K27m3-mediated gene silencing. 
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Figure 4.10: Adenovirus-mediated overexpression of EZH2α and EZH2β in GDM HUVECs.  
EZH2α and EZH2β overexpression was induced by adenovirus (Ad.) transduction. The relative 
expression of both EZH2 isoforms (normalized to β-actin) assessed by qPCR was successfully 
increased (A). Ad. EZH2β overexpression increased H3K27me3 levels in GDM-HUVECs, 
whereas Ad.EZH2α was ineffective as shown by Western blot analysis (B). All data are 
presented as mean ± SEM. ***P<0.001 vs. Healthy-HUVECs; +P<0.05 vs. Ad.Null; and 
Ʌ
P<0.05 
vs. Ad.EZH2α. The number of donors used to prepare the tested HUVECs is reported in each 
panel. 
 
4.6 MiR-101 downregulates EZH2 expression in GDM-HUVECs  
 
To confirm that miR-101 directly targets EZH2 for inhibition in GDM-HUVECs, we 
altered miR-101 levels by transfecting GDM-HUVECs with pre-miR-101 or anti-miR-
101 using a scramble sequence as a control (GDM-Scr). 
We first found that both pre-miR-101 and anti-miR-101 affected EZH2 mRNA 
expression (Figure 4.11 A). When looking specifically at the effect of miR-101 inhibition 
on each of the two EZH2 isoforms, we found that mRNA levels of both were increased 
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Figure 4.11: MiR-101 regulates EZH2 mRNA levels in GDM-HUVECs  
GDM-HUVECs were transfected with pre-miR-101, anti-miR-101 or a scramble sequence 
(GDM-Scr) to modulate miR-101 expression levels. Relative expression of EZH2 mRNA 
(normalized to β-actin) was reduced with pre-miR-101 transfection and increased with anti-miR-
101 transfection (A). Mir-101 inhibition similarly increased the relative mRNA expression 
(normalized to β-actin) of EZH2α and EZH2β (B). All data are presented as mean ± SEM. 
*P<0.05 and **P<0.01 and vs. GDM-Scr. The number of donors used to prepare the tested 
HUVECs is reported in each panel. 
 
In addition, pre-miR-101 decreased EZH2 protein (Figure 4.12 A) and H3K27m3 
expression compared to the scramble control (Figure 4.12 B). Finally, anti-miR-101 
increased EZH2 in GDM-HUVECs (Figure 4.12 A), but it did not change the overall 
H3K27m3 protein expression, as shown by Western blotting analysis (Figure 4.12 B). 
From these experiments we concluded that miR-101 targets EZH2 in GDM-
HUVECs and downregulates its expression. 
 
 
Figure 4.12: MiR-101 regulates EZH2 and H3K27m3 protein levels in GDM HUVECs 
The protein expression of EZH2 (normalized to laminin A/C) and H3K27me3 (normalized to H3) 
was negatively altered in GDM-HUVECs transfected with pre-miR-101, whereas anti-miR-101 
increased EZH2 (A), but not H3K27m3 protein (B). All data are expressed as mean ± SEM. 
*P<0.05 and **P<0.01 vs. GDM-Scr group. The number of donors used to prepare the tested 
HUVECs is reported in each panel. 
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4.7 GDM reduces EZH2 and H3K27m3 occupancy at the miR-
101 locus transcriptional regulatory region. 
 
Similar to protein coding genes, miRNAs are also susceptible to epigenetic 
modulation suggesting the existence of a regulatory circuit between epigenetic and 
miRNAs 95 In this context it has been demonstrated that EZH2 regulates miR-101 in 
ovarian cancer cells 115 
To understand whether EZH2 regulates miR-101 in GDM-HUVECs we looked at 
EZH2 and H3K27m3 occupancy within the promoter of the miR-101 locus. A scheme of 
the miR-101 promoter is presented as Figure 4.13. 
 
 
Figure 4.13: Scheme of miR-101 promoter regions 
Representation of the transcriptional location of the miR-101-1 gene (Ch1: 65.522.117–
65.526.191) derived from the University of California Santa Cruz (UCSC), Genome Browser 
GRCh37/ hg19. The red arrows show the transcription starting site (TSS) putative region and 
the regions amplified by the three set of primers used for the chromatin immunoprecipitation 
(ChIP). 
 
By performing chromatin immunoprecipitation (ChIP) with antibodies targeting 
EZH2 and H3K27m3, followed by qPCR for different miR-101 promoter regions (Table 
III, Materials and Methods), we found that EZH2 and H3K27m3 occupy the miR-101 
promoter in both healthy HUVECs and GDM-HUVECs (Figure 4.14 A). Moreover, in 
GDM-HUVECs, we observed decreased EZH2 and H3K27m3 occupancy at a 
regulatory sequence beginning at −396 bp upstream of the transcription start site 
(TSS), (Figure 4.14 A).  
Taking into consideration current paradigms, it is expected that reduced EZH2 
occupancy on the miR-101 promoter results in a higher accessibility of chromatin, 
thereby increasing miR-101 transcription in GDM-HUVECs. Indeed by performing 
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qPCR on GDM-HUVECs transfected with small interfering RNA for EZH2 (siEZH2), we 
found increased miR-101 expression (≈ 3.5 fold increase ± 0,564, P<0.05) after EZH2 
silencing compared to a siRNA scramble sequence (siRNA-Scr) (Figure 4.14 B).  
 
 
Figure 4.14: EZH2 regulates the promoter methylation status of miR-101  
Chromatin immunoprecipitation (ChIP) followed by qPCR showed that EZH2 occupancy on the 
transcriptional regulatory region (−396/+3 bp from the transcription start site [TSS]) of the miR-
101 promoter was reduced in GDM-HUVECs compared to Healthy-HUVECs (A), and 
consistently also H3K27m3 binding to this promoter region was decreased in GDM-HUVECs 
(B). IgG was used as a negative control. Data were calculated as % bound/input. Relative miR-
101 expression level (normalized to snRNAU6) increased in GDM-HUVECs transfected with 
small interfering RNA for EZH2 (siRNA-EZH2) compared with cells transfected with a siRNA 
scrambled sequence (siRNA-Scr) (C). All data are expressed as mean ± SEM. #P<0.05 vs. 
Healthy-HUVECs; *P<0.05 vs. siRNA-Scr. The number of donors used to prepare the tested 
HUVECs is reported in each panel. 
 
4.8 EZH2β inhibits miR-101 transcription in HUVECs 
 
To complement these studies, we performed luciferase reporter assays on healthy 
HUVECs overexpressing either EZH2α or EZH2β. Figure 4.15 shows that Ad-mediated 
EZH2β overexpression inhibits the transcriptional activity of the miR-101 promoter in 
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comparison with Ad.Null and EZH2α. EZH2α did not exert any significant effect on 
miR-101 promoter transcriptional activity. Taken together, these results suggested that 




Figure 4.15: MiR-101 transcription in HUVECs is regulated by EZH2β  
Transcription reporter assay performed in healthy HUVECs showed a significant decrease of 
miR-101 promoter activity after Ad-mediated EZH2β but not after EZH2α overexpression 
compared to Ad.Null. *P<0.05 vs. Ad.Null and 
Ʌ
P<0.05 vs. Ad.EZH2α. The number of donors 
used to prepare the tested HUVECs is reported in each panel. 
 
4.9 In vitro exposure of healthy HUVECs to high concentrations 
of glucose lowers EZH2 binding to the miR-101 promoter and 
increases miR-101 expression 
 
Next, we wanted to investigate whether exposure of normal HUVECs to high 
concentrations of glucose (HG) in vitro may recapitulate the molecular changes 
observed in HUVECs from GDM pregnancies.  
To this end, healthy HUVECs were exposed to high (25 mM) or normal glucose 
concentrations (5 mM) for 48 hours, using L-glucose as an osmotic control (20 mM). 
ChIP was used to measure EZH2 binding to the abovementioned miR-101 promoter 
region beginning at around −396 bp upstream of the TSS. Indeed, similar to GDM, we 
found that in vitro cell exposure to HG reduced the presence of EZH2 at this miR-101 
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promoter regulatory region (Figure 4.16 A). Moreover, congruent with the results from 
ChIP assays, HG increased miR-101 levels in healthy HUVECs (Figure 4.16 B).  
Taken together, our data suggest that EZH2 and miR-101 are reciprocally regulated 
in HUVECs and that an imbalance of this equilibrium in response to either in vivo GDM 
or in vitro exposure to HG might result in a lower EZH2 occupancy of the miR-101 
locus, thus leading to increased miR-101 transcription and further phenotypic 
alterations of ECs. 
 
 
Figure 4.16: Exposure to high glucose (HG) reduces EZH2 occupancy at the miR-101 
promoter in HUVECs  
Healthy HUVECs were exposed to normal D-glucose (NG; 5 mmol/L) or high D-glucose 
concentrations (HG, 25 mmol/L), with 20 mmol/L L-glucose as an osmotic control, for 48 hours. 
HG was intended to mimic diabetic hyperglycemia. ChIP analysis followed by qPCR revealed a 
lower EZH2 occupancy at the miR-101 locus regulatory region (−396/+3 bp from the TSS) 
under HG. IgG was used as a negative control. Data were calculated as % bound/input. (A). 
MiR-101 expression was increased in HG compared with NG with osmotic control (B). All data 
were expressed as mean ± SEM, *P<0.05 vs. NG. 
 
4.10 Effect of EZH2 overexpression on phenotypic alterations in 
GDM-HUVECs 
 
To see whether restoring EZH2 levels in GDM-HUVECs could rescue the cell 
survival, proliferation and angiogenic capabilities, we transduced GDM-HUVECs with 
Ad.EZH2α or Ad.EZH2β using an empty vector as control (Ad Null). Ad.EZH2β 
decreased the relative apoptotic activity (Figure 4.17 A) but did not rescue impaired 
proliferation (Figure 4.17 B). Moreover Ad.EZH2β increased the migratory capacity of 
GDM-HUVECs (Figure 4.17 C) but did not have any effect on tube formation (Figure 
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4.17 D). Ad.EZH2-α did not alter the behavior of GDM-HUVECs (Figures 4.17A-4.17D). 
Taken together, these data suggest that a deficit in EZH2β contributes to some of the 
functional defects induced by GDM in fetal endothelial cells.  
 
 
Figure 4.17 Effect of Ad.-mediated EZH2 overexpression on functional capacities of GDM-
HUVECs 
GDM-HUVECs were infected with adenovirus carrying EZH2α, EZH2β, or an empty vector 
(Ad.Null). Ad.EZH2β rescued GDM-HUVEC survival (A) and showed no effect on cell 
proliferation (B). Moreover, Ad.EZH2β improved the migration capacity of GDM-HUVECs (C), 
whereas it exerted no effect on tube formation (presented here as tube length in mm) (D). In all 
tests, Ad.EZH2α produced a similar effect to Ad.Null. (Scale bars 0.5 mm). Data are presented 
as mean ± SEM. *P<0.05 vs. Ad.Null. The number of donors used to prepare the tested 
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Chapter V – Discussion and Conclusions 
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Gestational diabetes mellitus (GDM) is a common medical complication in pregnancy 
and is associated with adverse long-term outcomes for the offspring. GDM leads to 
fetal hyperglycemia and endothelial dysfunction in the fetal circulation where it might be 
responsible for the increased incidence of type 2 diabetes (T2D) and cardiovascular 
disease (CVD) observed later in life 2–4. Clinical trials and epidemiological studies in 
patients with either T1D or T2D have demonstrated that exposure to prolonged 
hyperglycemia leaves a long-lasting impression on vascular cells leading to the 
development of vascular complications which persist even after glycemic control is 
achieved. However, the same studies also suggested that a good glycemic control can 
delay the onset of vascular complications in diabetic subjects 5.  
Accumulating evidence suggests a key role for epigenetic mechanisms such as 
DNA methylation, histone post-translational modifications, and non-coding RNAs in the 
complex interplay between genes and the environment. Factors associated with the 
pathology of diabetic complications, including hyperglycemia, oxidative stress and 
inflammatory factors might lead to dysregulation of these epigenetic mechanisms and 
alter the expression of genes involved in endothelial cell homeostasis, without changes 
in the underlying DNA sequence. Furthermore, long-term persistence of these 
alterations may be a key mechanism underlying the phenomenon of “metabolic 
memory” and progression of endothelial dysfunction despite the achievement of 
glycemic control. Current strategies to prevent diabetes and its vascular complications 
have not been fully efficacious 143, thus a study of the epigenetic mechanisms occurring 
during fetal development in the diabetic environment would represent an early strategy 
to prevent T2D and CVD in adulthood.  
In this study we have provided a novel underlying mechanism involving miR-101 
and Enhancer of Zeste Homologue 2 (EZH2), in GDM-elicited fetal endothelial 
dysfunction. The first goal was to characterize the effect of GDM on fetal endothelial 
cell (EC) functionality. To this end we have isolated human umbilical vein endothelial 
cells (HUVECs) from the umbilical cords of GDM mothers. These cells are an 
expedient in vitro model for the study of the molecular consequences of long-term 
exposure to chronic hyperglycemia. A few studies have shown some biochemical 
alterations such as impaired NO bioavailability 140 as well as increased adhesion 
molecule protein levels 67 in HUVECs isolated from GDM-mothers. Here, we have 
reported that GDM-HUVECs present an increased rate of apoptosis and a decreased 
proliferation compared to HUVECs isolated from healthy-pregnancies. Moreover we 
have found a decrease in migration and angiogenic capabilities, measured by means of 
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scratch assays and tube formation on Matrigel respectively. These data have provided 
a functional characterization of GDM-HUVECs contributing to extend the knowledge on 
the effect of the intrauterine environment on fetal endothelium. Moreover, these 
analyses have been performed after cells were expanded in normal D-glucose 
concentrations (5mM) for 5 to 6 passages, suggesting that the cells were still affected 
by the chronic hyperglycemia sensed in utero, which is consistent with the existence of 
a metabolic memory.  
The second objective of this study was to investigate on the role of epigenetic 
factors and miRNA in the functional alterations observed in diabetic ECs. A previous 
study has shown that miR-101 regulates endothelial function and angiogenesis by 
inhibiting EZH2 transcription in ECs under physiological glucose conditions (Smits et al. 
2011). Similarly, our data have demonstrated that GDM is associated with an increase 
of miR-101 expression and a reduction of its target EZH2, mainly of the EZH2β 
isoform. EZH2 is essential for the epigenetic maintenance of the trimethylation of lysine 
27 on histone H3 (H3K27me3) 112 and its decrease would lead to a reduction of the 
H3K27me3 mark, as we have found in GDM-HUVECs, and subsequently to a 
diminution of EZH2-mediated gene silencing. Accordingly, a recent study has identified 
946 genes upregulated by >2-fold due to EZH2 knockdown, in line with its repressive 
function. Importantly, many of these genes are implicated in endothelial cell dysfunction 
and cardiovascular disease 116.  
In this study we have found a novel underlying mechanism involving miR-101 and 
EZH2 in GDM endothelial dysfunction. We have identified that in HUVECs, EZH2 is 
both a target of, and a transcriptional repressor for, miR-101. By performing chromatin 
immunoprecipitation (ChIP) we have shown that increased miR-101 expression, in both 
GDM-HUVECs and HUVECs exposed to high concentrations of glucose in vitro 
(25mM), is associated with reduced EZH2 binding at transcriptional regulatory regions 
of the miR-101 gene promoter and reduced H3K27me3 (within 0.5 kb of transcription 
starting site). The reduced H3K27me3 mark results in higher chromatin accessibility to 
transcription factors and consequently to an increase in miR-101 transcription. 
Consistently, we have also shown that EZH2 knockdown increased miR-101 
expression in HUVECs. This result is consistent with the knowledge that miRNAs and 
their target genes are often linked in a regulatory feedback loop, which maintains their 
homeostatic expressional balance 144. Additionally, we have found that among the two 
recently identified EZH2 isoforms 9, EZH2β is the only one which is both a target of 
GDM and a mediator of some of the GDM-HUVECs’ endothelial dysfunction.  
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Our data also suggest that some defects of GDM are mediated by miR-101 
independently of EZH2β. In fact, although miR-101 inhibition rescues most of the 
studied cell functions in GDM-HUVECs, Ad-mediated EZH2β only improved cell 
survival and migration. This can be explained with the knowledge that miR-101 acts 
post-transcriptionally on multiple target genes, including EZH2 and vascular endothelial 
growth factor A 145. A possible limitation of our study is that we have not identified all 
the miR-101 target genes involved with the GDM-induced vascular defects. Moreover, 
because EZH2 regulates the transcription of different genes, the rescue effect of 
EZH2β can be mediated by the inhibition of a number of damaging genes.  
Taken together, our data suggest that EZH2 and miR-101 are reciprocally regulated 
in HUVECs; EZH2 is both a target of and a transcriptional repressor for miR-101. In 
GDM this equilibrium is compromised resulting in a lower EZH2β occupancy of the 
miR-101 promoter, thus leading to increased miR-101 transcription and further 
phenotypic alterations of ECs. This altered miR-101/EZH2 equilibrium could continue to 
influence vascular gene expression and function well after birth thus contributing to the 
cardiovascular complications of GDM in the offspring.  
Our study is in line with the concept of a “glycemic memory” where in vivo or in vitro 
exposure to chronic hyperglycemia leads to persistent changes in vascular cells, 
through dysregulation of the underlining epigenetic mechanisms.  
This findings provide new insights about the epigenetic pathways activated by GDM 
in utero, providing new targets for future therapeutic interventions. MiRNA-based 
therapeutics is still in the early stages; however, inhibition of some miRNAs has been 
promising for the future treatment of vascular diseases 134,135. With the focus on the 
observed changes in EZH2 levels, it would appear conceivable to target miR-101 for 
inhibition in GDM.  
In future studies, it would be worth attempting to correlate miR-101 levels in 
HUVECs with its levels both in the fetal and in the maternal blood at different phases of 
pregnancy. This could lead to the development of miR-101 as a circulating biomarker 
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